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Prostate cancer is among the leading causes of cancer-related death in the United 
States with 30,000 people succumbing to the disease every year. A vast majority of 
these men, at the time of diagnosis, presented with distal prostate cancer as opposed to 
cancer that was contained within the primary organ. Currently, there is no cure for 
metastatic prostate cancer despite novel therapeutic advances which have been made 
over the last 15 years. Our lab is interested in molecular engineering strategies that 
selectively poison cancer cells but do not affect normal cells. Because a majority of 
prostate-derived tumors grow very slowly, traditional anti-proliferative cytotoxic 
chemotherapies are largely ineffective. Therefore, we have selected an array of cytotoxic 
agents that kill cells regardless of their stage in the cell cycle. These agents, Pro-
aerolysin, Granzyme B, and Pseudomonas Exotoxin A, are all protein weapons found in 
nature that have evolved millions of years to efficiently kill eukaryotic cells. Because 
these weapons all must be regulated to prevent off-target toxicity, we propose to modify 
the regulatory steps involved in these toxins’ mechanisms in order to selectively kill 
prostate cancer cells. We aim to do this in a myriad of different ways using previously 
discovered modifications and mutations made to these agents which have been shown 
to modulate their activity. Specifically, we intend to engineer these toxins’ ability to bind 
to cells more selectively or to be activated by enzymes selective for the prostate cancer 
micro-environment. This work will specifically discuss the rationale behind each 
modification, demonstrate the synthesis and purification of each protein, and assess the 
biological activity of each in respect to prostate cancer. Ultimately, we hope that the 
lessons learned from this study will serve as a useful case study in biochemical 
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Introduction: Current Status of Prostate Cancer Therapeutics and Biologic-based 
Targeted Agents 
Prostate Cancer Overview 
In the year 2016, over one hundred and fifty thousand men were diagnosed with 
prostate cancer in the United States (1). Prostate cancer cases represent almost a third 
of all cancer diagnoses in men and roughly one tenth of all total cases in human beings. 
The average number of cases diagnosed each year has steadily declined over the past 
decade (1), likely due to changes in practice by physicians who feel that the disease is 
currently being over-diagnosed and unnecessarily treated. Despite this, the overall 
prevalence of this malignancy in the Western population is a public health concern that 
will continue to challenge healthcare providers and researchers for decades to come due 
to the subset of patients with aggressive, therapy resistant, and ultimately , fatal disease.  
Perhaps the most astonishing statistic associated with prostate cancer is the survival 
rate when compared with other solid tumors. It is estimated that the overall 5-year 
survival rate for men with prostate cancer is approximately 99% (1). Perhaps even more 
astonishing is that an overwhelmingly vast majority of patients who succumb to prostate 
cancer are diagnosed with metastatic tumors as opposed to localized or regional 
disease. This is clearly estimated in the survival rates within these patients. Men 
presenting with local or regional disease at time of diagnosis are almost always are alive 
after 5 years, with the respective survival rate for these tumors approaching 100%. 
Given this statistic, it is unprecedented that twenty six thousand men died of prostate 
cancer in 2016 (1). Because men with non-metastatic disease have disproportionately 
high survival rates when compared to those that do, the primary focus in the fields of 
diagnostics, therapeutics, and tumor biology is on metastatic prostate cancer (MPC).  
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MPC is the number two leading cause of cancer death in the United States in men. 
Unlike other stages of prostate cancer, the five year survival rate for this disease is 25%. 
Unfortunately, while some advancements have been made in the realm of therapeutics, 
there has been little improvement in overall survival of MPC over time. This is primarily 
due to the nature of MPC tumors, as they seem to be inherently resistant to most genres 
of therapy. Currently, most therapeutic strategies approved to treat MPC are primarily 
palliative and improve survival in patients only marginally. If we are to make substantial 
advancements in prostate cancer therapy, new, innovative, and comprehensive 
strategies must be developed based on lessons learned from currently approved 
therapies and insights into normal and malignant biology.  
Currently Approved MPC Therapies 
While there is currently no approved curative therapy for MPC, there exists a slowly 
growing range of therapeutic options that can effectively improve patient health, optimize 
quality of life, and reduce overall tumor burden.  Probably the most studied and most 
utilized arms of MPC therapy is hormone therapy. MPC tumor cells, like localized 
cancers, are biochemically addicted to Androgen-dependent growth, pro-survival, and 
anti-apoptotic signals via Androgen Receptor (AR)-driven transcriptional programs. 
Current, there are two methods of targeting this pathway using chemical means. The 
first is Androgen Depravation Therapy (ADT) (2) in which a LHRH agonist is 
administered to the patient thus augmenting their testosterone signaling axis and thus 
decreasing systemic concentrations of testosterone over time. The other, anti-androgen 
therapy, which is usually reserved for castration resistant prostate cancer, involves 
chemically targeting AR with molecules that bind directly to the protein and inhibit its 
ability to bind testosterone and undergo the molecular changes necessary to affect gene 
transcription (3,4). It has also been shown that blocking the synthesis of androgens can 
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also generate similar effects via inhibitors of Cyp17 (5).  Both modes of therapies inhibit 
cell growth and arrest the tumor in the G0 phase of the cell cycle. Like ADT, anti-
androgens are most effective when combined with another mode of therapy.  
 
Recently, it has been shown that the cytotoxic chemotherapeutic agent, docetaxel, 
substantially improves survival and quality of life in men with MPC when combined with 
enzalutamide(6,7),  (a second generation anti-androgen) and prednisone (for pain 
management). Docetaxel is a classical anti-cancer chemotherapeutic which kills rapidly 
replicating cells via stabilization of microtubule structures in cells thus arresting mitosis 
and leading to cell death (8). It is, therefore, paradoxical that prostate cancer cells are 
among the slowest of human tumors and hardly respond to other chemotherapeutic 
agents. Therefore, it is likely that docetaxel and other microtubule-targeting agents affect 
prostate cancer cells via a mechanism independent of proliferation. This problem was 
resolved by Zhu et al in 2010 when they showed that docetaxel directly inhibited the 
trafficking of AR to the nucleus of prostate cancer cells (9). This rendered ligand-bound 
AR unable to access its chromatin binding partners which allows the receptor  to 
facilitate transcription of target genes and promote tumor cell survival. It is, therefore, to 
be expected that Taxol-based compounds would synergize with anti-androgens, as they 
both offer unique and effective methods of inhibiting AR signaling, on which MPC cells 
are dependent. Clearly then, MPC cell targeting cannot be successfully implemented 
using strategies that involve inhibiting proliferation or DNA replication directly due to 
MPC cell growth rates, tendency to remain in the G0 stage of the cell cycle, and 
resistance to classical chemotherapeutics.  
Another arm of anti-cancer treatment that has arisen in very recent years is 
immunotherapy. Specifically for MPC, the currently approved Sipuleucel-T has been 
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shown to significantly extend the lifespans of patients with advanced prostate cancer 
(10). Sipuleucel-T is administered by removing a patient’s own dendrocytes and 
incubating them with a fusion protein containing two factors. The first is the prostatic acid 
phosphatase (PAP) which is a membrane-bound enzyme present on a majority of 
prostate cancer cells. This portion of the fusion exposes the immune cells to a cancer-
selective antigen which should induce an immune response upon presentation in vivo. 
The second component of the fusion protein is GM-CSF, a protein which has been well 
characterized to stimulate the differentiation of dendrocytes into monocytes, neutrophils, 
basophils, and other pro-inflammatory cells. The, now matured, cocktail of immune cells 
is then re-administered to the patient and will go on to target the tumor. Sipuleucel-T can 
also be combined with the aforementioned strategies to further perturb tumor function 
and improve therapeutic responses (11). One major obstacle of Sipuleucel-T and other 
immunotherapies for MPC is the immunosuppressive micro-environment created by the 
tumor cells. While not fully understood, it is clear that tumor cells and –reprogrammed 
stromal cells are capable of recruiting other cell types that directly inhibit migration and 
function of various subtypes of inflammatory cells. Most notably, the MPC 
microenvironment has been shown to be rich in mesenchymal stem cells, myeloid 
derived suppressor cells, and T-regulatory cells, all of which have been shown to locally 
inhibit anti-tumor immune responses (12, 13). This not only limits the efficacy of most 
immunotherapies but also inhibits the utility of immune checkpoint inhibitors, as anti-
tumor lymphocytes cannot effectively localize in the prostate cancer microenvironment. 
In order to improve the functionality of immunotherapies for MPC, we must first 
overcome this obstacle and aim to re-program anti-inflammatory signaling present in the 
tumor.  
Attractive Markers for Novel MPC Therapeutics 
5 
 
In this work, our lab aims to utilize a diverse set of protein agents to generate new 
strategies to combat MPC. These agents all have been well characterized to kill 
mammalian cells of all types using robust mechanisms of inducing cell death. We aim to 
engineer these agents to either selectively kill anti-inflammatory immune cells thus 
improving immunotherapy efficacy or to directly target tumor and pro-tumor stromal cells 
based on the unique expression of prostate-selective enzymes. Because these proteins 
are all highly toxic to normal cells and do not greatly discriminate to which cell types they 
kill, we must use protein engineering approaches to re-target these agents to kill only 
cells in the tumor microenvironment and limit systemic toxicity which would otherwise 
minimize the usefulness of these drugs.  
Of all markers of interest that have been used to hone a cytotoxic payload to a human 
tumor, the Prostate Specific Antigen (PSA) is among the most selective. PSA is a 
secreted serine protease with chymotrypsin-like activity (14). It is expressed by both 
normal and malignant prostate epithelial cells at amounts much higher than any other 
tissue in the body. Function wise, it is not completely clear what PSA’s physiological 
biological role is, however, it does seem to contribute to semen liquefication following 
ejaculation in order to promote sperm motility (15). There is also evidence that PSA can 
cleave members of the complement system in order to regulate toxicity associated with 
chronic inflammation (16). Regardless, PSA has been shown to be overproduced by 
prostate derived tumors and is a well characterized biomarker of disease burden in men 
with both localized and advanced cancer. In men with MPC, it is likely that the patient 
has had a radical prostatectomy as an early therapeutic approach to maintain his 
disease. Because the two major sinks of PSA production are the prostate and prostate-
derived tumors, men who have had surgery almost exclusively express PSA in their 
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tumor relative to the rest of the body. Thus, drugs requiring activation by PSA cleavage 
would be selective if not specific for the tumor in a man with MPC.  
Due to the fact that PSA is both overproduced by MPC tumors and is lowly expressed in 
any other tissue, our lab has become interested in its enzymatic activity. Because PSA is 
found systemically throughout the body due to leaky tissue architecture in a man with 
prostatic disease, a PSA-activated pro-drug may be  systemically activated by PSA that 
has leached into the bloodstream. To address this issue, our lab designed a highly 
selective PSA peptide substrate containing the amino acid sequence HSSKLQ and 
conjugated a fluorescent amino-methyl-coumarin reporter to it which is quenched upon 
conjugation. Upon PSA or PSA-like hydrolysis after the glutamine residue,  the free 
fluorophore is released. To quantify PSA’s enzymatic activity, our lab immuno-
precipitated PSA from the extracellular fluid of MPC tumors and from serum from 
patients with MPC. To our surprise, we found that PSA’s unique enzymatic activity was 
completely inhibited in serum from these patients as opposed to being almost 100% 
active in the extracellular fluid from the tumor (17). Later, it was found that PSA is rapidly 
inhibited by covalent protease inhibitor proteins present in abundance in the 
bloodstream. These proteins, alpha-1-antichymotrypsin and alpha-2-macroglobulin form 
irreversible adducts with PSA which can be detected in serum of patients with MPC (18). 
Because PSA is abundant in the extracellular space of tumors compared to other 
tissues, inactive in the bloodstream, and capable of cleaving highly sophisticated 
substrates selectively, it is an ideal candidate to target cytotoxic proteins to MPC cells 
via pro-drugs strategies. These pro-drugs, in theory, will be cytotoxic agents that are 
rendered inactive with an inhibitory peptide attached. This peptide will be linked to the 
agent of interest using a peptide substrate of PSA. For more potent cytotoxins, the 
substrate HSSKLQ was found to be a less efficient yet more specific substrate for PSA. 
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For less cytotoxic agents, the substrate KGISSQY is more robustly cleaved but also 
processed by other proteases (19). Previously characterized PSA-activated pro-drug 
cytotoxic agents include the plant  toxin thapsigargin (20), an N-(2-hydroxypropyl) 
methacrylamide copolymer (21), phosphoramide mustards (22), and the bacterial toxin 
pro-aerolysin (23). All of which were shown to be toxic selectively to cells in the 
presence of enzymatically active PSA in various tissue culture and animal models.   
Another attractive prostate cancer marker is the Prostate Specific Membrane Antigen 
(PSMA). PSMA is a carboxy-peptidase enzyme also expressed robustly by prostate 
epithelium (24). Its function in normal prostate biology is not well characterized but 
PSMA has been shown to process the neurotransmitter N-acetyl-aspartyl-glutamate 
(NAAG) into NAA and free glutamate via cleavage of the conjoining amide bond linking 
the two amino acids (25). PSMA is highly up-regulated in castrate resistant prostate 
cancer due to its negative regulation by AR. In the context of prostate cancer, PSMA’s 
role in oncogenesis is not clear. It has been suggested that PSMA acts as a folate 
scavenger via internalization folate substrates under low folate conditions but this 
mechanism is still somewhat controversial (26). PSMA, recently, has been suggested as 
a predictive biomarker for aggressive prostate cancer. This is because PSMA has been 
shown to be overexpressed in patients who eventually have recurrent, more aggressive 
disease. In patients whose tumor cells were approximately 85% positive for PSMA, it 
was shown that they were not only more likely to relapse but were also more likely to 
relapse faster than patients who did not (27, 28). PSMA has also been shown to be 
extensively recycled on the cell membrane in that it is constantly being enveloped into 
the cell and re-shuttled back to the cell membrane. PSMA’s enzymatic activity, strong 
correlation with aggressive cancer, and high turnover rate have made it an attractive 
marker for tumor-targeted therapeutic and imaging agents.  
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There are several reports by various groups developing PSMA-targeted therapeutic and 
diagnostic molecules for MPC. Most notably, two antibody conjugates are currently in 
clinical trials for the treatment of MPC. The first, J591, is a monoclonal antibody against 
PSMA which was successfully conjugated to 177Lu (29). This radio-immunotherapy was 
shown in Phase II clinical trials to be tolerated by patients with a reasonable toxicity 
profile while generating partial responses in patients and lowering PSA levels. Another 
monoclonal antibody,     MLN2704, was successfully fused to  maytansinoid 1, a 
cytotoxin with Taxol-like functionality, and has shown some clinical benefit in a Phase I/II 
trial in which several patients observed some benefit of the drug when dosed (29). 
Other, less conventional strategies, have also had clinical success. Recently, the lab of 
Dr. Martin Pomper has developed a class of urea-linked dipeptide inhibitors of PSMA. 
These molecules display remarkable potency and specificity for PSMA despite having an 
extremely simple chemical structure. It has been recently shown that these agents can 
successfully deliver imaging agents to MPC tumors as well as radiopharmaceuticals (30, 
31). Currently, a ‘urea’ molecule linked to 18F, known asF-18 DCFPyL  is in clinical trials 
for the detection of MPC tumors on PET scans (32) and a 99mTc-linked urea is also being 
evaluated as a diagnostic agent for MPC (33). Rather than targeting PSMA as a means 
to internalize agents of interest, there are also efforts to target cytotoxic molecules to 
MPC tumors via PSMA’s enzymatic activity. Currently, a molecule known as G202, is in 
clinical trials for the treatment of liver cancer. G202 is a poly-glutamated analog of the 
potent plant-based toxin thapsigargin (34). G202 can be given safely systemically due to 
being in an inactive conformation. Once in the MPC environment, PSMA can cleave 
these glutamate residues selectively and release the free toxin. It should be noted that 
PSMA is also expressed on neo-vasculature in tumors which explains why it can be 
utilized for other tumor types that don’t inherently express PSMA (35). It is evident that 
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conjugating agents with therapeutic and diagnostic potential to PSMA antibodies, scFvs, 
inhibitors, and substrates is a well-studied and growing field in MPC research and is 
likely so successful due to PSMA’s previously discussed biological and biochemical 
properties.  
Biologics in Cancer  
The primary goal of this work is to characterize the biochemical and pharmacological 
properties of various engineered biologic-based toxic proteins for their use as systemic 
MPC therapeutics. Our lab is very interested in the utilization of novel protein agents to 
treat MPC. One major reason for this interest is the natural tendency for proteins to 
accumulate in the microenvironment of tumors via the enhanced permeability and 
retention (EPR) effect. The EPR effect is a phenomenon in tumor biology in which large 
macro-molecules have a greatly increased retention time in tumors than in normal tissue 
(36). This is due primarily to two different physiological properties of tumors. The first is 
that neo-vasculature formed in the cancer stroma tends to be compromised which 
causes material from the bloodstream to leak into the tumor at rates higher than normal 
tissue. The second is that most tumors do not have well established lymphatic drainage 
in and around the stroma. Thus, an increase in material flowing in and little to no 
sufficient drainage from the tumor yields a net accumulation of molecules above ten 
thousand Daltons. This makes utilizing large macromolecules naturally advantageous for 
cancer therapy, as the tumor’s own physiology can be used against it as a means to 
selectively concentrate cytotoxic agents in the adjacent space to the tumor cells.  
Naturally, due to our understanding of the EPR effect, a large increase in molecular 
details with respect to tumor biology and biochemistry, and a spike in recombinant 
technologies, protein-based cancer therapeutics have become immensely popular in the 
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past two decades. Since the year 2013 alone, there have been dozens of monoclonal 
antibodies and other biologic-based therapies to treat human cancers. These agents 
provide remarkable selectivity for their respective antigen and can efficiently deliver 
some of the most lethal cytotoxins known to human biology to cancer cells while 
minimizing toxicity (37). These agents can also be used to ‘tag’ tumor cells for 
destruction by the immune system and the antibody-dependent cell cytotoxicity pathway 
as well as interfere with extracellular pro-tumor signaling pathways such as the 
immunosuppressive PD1-PDL1 signaling system (38). As the demand for new therapies 
for MPC grows, thus does the need for new strategies to target tumors with these 
agents. Despite an overwhelming amount of success from a biochemical and molecular 
standpoint, there are currently no approved biologics for either local or distal prostate 
cancer. In order to develop such an agent, potent cytotoxins must be engineered 
appropriately to target prostate cancer cells selectively. In this work, we discuss new 
methods to regulate the toxicity of 4 different human and bacterial toxic proteins into 4 
novel therapeutic strategies each with its own advantages and pitfalls.  
Pro-Aerolysin, Granzyme B, and Pseudomonas Exotoxin A Overview  
In order to develop novel, targeted protein toxins for the treatment of MPC, we selected 
three protein ‘toxins’ due to their unique mechanisms of action as well as their ability to 
be regulated via biochemical switches and conditions. Pro-aerolysin (PA) perhaps 
exemplifies this principle the most. PA is a bacterial pro-toxin produced by the infectious 
prokaryote Aeromonas Hydrophila (39). Secreted as an inactive dimer, PA binds to GPI-
anchored proteins on target cell surfaces and is proteolytically processed by the trypsin-
like protease furin near the C-terminus of the toxin (40, 41). Proteolysis of the toxin 
releases an inhibitory peptide which, upon removal, stabilizes a conformational change 
which allows the protein to oligomerize from the inactive dimer to a pore-forming 
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heptamer (42). This structure internalizes into the cell membrane inducing rampant cell 
lysis and subsequent cell death. This mechanism of targeted cell lysis is an attractive 
power to harness for therapeutic purposes, as it is very difficult for tumor cells and 
neighboring stromal cells to become resistant to plasma membrane damage.  
PA has two steps in its mechanism in which it can be regulated. The first is the cell 
binding step which allows the protein to concentrate on the plasma membrane allowing 
for hepatmerization to occur. It was shown that a simple point mutation, R336A, 
obliterates binding to GPI-anchored proteins in the cell, thus making the protein several 
orders of magnitude less toxic. It was also shown that attaching ligands and/or binding 
moieties to the N-terminus transforms the protein from an inactive mutant into a selective 
immunotoxin. Specifically, the cytokine IL2 was fused to R336A and was shown to 
selectively kill IL2 producing tumor cells both in vitro and in vivo (43). The other critical 
step that is exploitable for therapeutic engineering purposes is the proteolytic activation 
step. Recently, our lab mutated the furin activation sequence near PA’s C-terminus and 
inserted the HSSKLQ PSA substrate thus generating a mutant PA, deemed PRX302, 
which was selectively activated by functional PSA (23). PRX302 was shown to be 
selectively toxic to cells in culture in the presence of PSA and had anti-tumor activity 
against PSA producing lines in vivo when injected intratumorly. Unfortunately, this agent 
cannot be given systemically due to the non-discriminant GPI-binding properties of the 
toxin. In this work, we explore the utilization of both engineered mutants of PA. First, we 
explore the capacity of IL2-R336A to target IL2-expressing immune cells in vivo and 
augment efficacy of anti-tumor immunotherapies. Second, we assess the feasibility of 
bypassing the limited systemic availability of PRX302 using controlled release methods 
via PLGA microparticles.  
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Because unique bacterial toxins are likely to induce immune responses which would 
decrease the efficacy of the drug and increase systemic toxicity, our lab has become 
interested in the utilization of protein agents that do not illicit an immune response. The 
most straightforward approach to this problem is to, simply, use toxins that are of human 
origin. Granzyme B (GZMB) is a secreted, caspase-like serine protease produced by 
cytotoxic CD8+ T-lymphocytes upon activation by an antigenic cell (44). Once the cell 
secretes GZMB, it is delivered into the endosome of the target cell via a calcium-induced 
membrane repair response (45) induced by the pore forming protein perforin, a co-
secreted factor with homology to members of the complement pathway. Once in the 
endosome, GZMB can translocate to the cytoplasm via perforin pores in the vesicle 
membrane (46). Once liberated, GZMB will proteolytically process a vast array of 
intracellular substrates such as members of the caspase family, Bcl2, and the apoptosis 
inhibiting ICAD protein (47). This causes a global apoptotic response in the cell leading 
to cell death. Like PA, we are interested in regulating GZMB’s activity to prostate cancer 
cells. This can be done in two different ways. The first is by regulating its proteolytic 
activation. While GZMB, at low concentrations, is harmless to cells in an extracellular 
context, at high concentrations it has been shown that GZMB can cleave substrates in 
the extracellular matrix and disrupt tumor cell growth and viability (48). This is an 
attractive ‘field effect’ therapy that could induce large scale damage to the tumor integrity 
and structure. However, this activity must be specific to the MPC tumor. In order to avoid 
inducing auto-apoptosis, CD8+ T-cells express GZMB as an inactive zymogen. The pro-
form of this protein contains an N-terminal inhibitory dipeptide with the sequence G-E. 
Upon store in the granule compartment of the cell, pro-GZMB is activated by Cathepsin 
C between the glutamate residue and isoleucine 3 releasing the active enzyme (49). 
Compartmentalization and pH of the cytotoxic granule minimizes the effects of GZMB on 
T-cell viability. Because PRX302 mutagenesis was rather easy  when converting the 
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wildtype protein into a PSA-activated pro-drug, we aim to do the same with GZMB. This 
mutant will be catalytically inactive until encountering functional PSA in the tumor 
microenvironment and be able to affect tumor cells, stromal cells, and other adjacent 
pro-tumor cells via re-modeling of the extracellular protein content. 
Another method of engineering GZMB to target MPC tumors is regulating internalization 
of the protein by attaching a targeting moiety to its C-terminus, similar to other 
immunotoxins developed utilizing monoclonal antibodies and scFv fragments delivered 
GZMB as a payload (50). This is an attractive strategy, as GZMB requires the presence 
of perforin in order to be functional which should render the drug very safe at reasonable 
doses. To assess GZMB’s use as a MPC-targeting cytotoxin, we aim to make protein 
drug conjugates using the catalytic domain of this enzyme fused to inhibitors of PSMA. 
These inhibitors will, in theory, bind PSMA, and facilitate the intracellular delivery of 
GZMB allowing it to induce apoptosis on the target cell thus killing it. Because GZMB 
activates several, independent, arms of the apoptosis pathway, we would expect tumor 
cells to be unable to develop a resistance to this therapy. The major pitfall of this therapy 
is whether or not the GZMB cargo would be able to translocate into the cytoplasm and 
access its substrates. To explore and rectify this problem, we also intend on evaluating 
and characterizing the activity of the potent bacterial toxin fragment, Pseudomonas 
Exotoxin (PE) A, called PE35 (51, 52). This toxin has been shown to internalize into cells 
when conjugated to a cell binding moiety such as a growth factor or monoclonal 
antibody, translocate into the cytoplasm, and inhibit protein synthesis thus arresting the 
cell growth and killing it. We chose this toxin due to its well characterized mechanism of 
cell targeting, its ability to escape the endosomal compartments, and its success as a 
cytotoxic payload in various immunotoxin platforms. In fact, one such agent, 
Moxetumomab-pasudotox which contains an anti-CD22 monoclonal antibody fused to a 
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fragment of PE is currently in Phase III trials for the treatment of Hairy Cell Leukemia 
(53). This protein is especially exciting, as it has been shown to be engineered to lack 
antigens that would lead to decreased tolerance by the immune system thus making the 
toxin ‘humanized’ (54). PE35 is a nice alternative to GZMB due to its drastically different 
mechanism of action and success as an anti-cancer pharmaceutical. The two diverse 
agents will paint an informative picture regarding the types of protein-based cytotoxins 
that can be successfully delivered into MPC cells via PSMA targeting.  
This study exhibits a multi-strategy approach to evaluate targeting protein toxins to the 
prostate cancer microenvironment using protein engineering and drug delivery 
principles. We intend to evaluate the biochemical and pharmacological principles of each 
method and evaluate their potential as novel cancer therapies. Lessons learned from 
this study will elucidate the limitations of each approach and provide insight into which 
strategies and protein-based agents have the most potential to move forward into more 
advanced pre-clinical studies and beyond. Ultimately, we hope that this will contribute to 
the greater understanding of the roll that biologic based agents can play in treating 
prostate cancer and other solid tumors which will help yield more effective treatments 
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Chapter 1: A Potent IL-2R Targeting Pro-drug as a Novel Anti-tumor Vaccine 
Adjuvant 
 
Immuno-therapies offer an exciting approach to anti-cancer therapy. Unfortunately, there 
are currently only two anti-tumor vaccines approved for the treatment of human cancer. 
The immunosuppressive properties of the microenvironment is likely responsible for 
some of the failures observed by these anti-cancer vaccines.  One strategy to improve 
vaccine efficacy is to target this microenvironment with a selectively toxic chemical 
adjuvant. To do this, we employ the usage of a chimeric protein containing IL-2 and a 
binding mutant of the bacterial toxin Pro-aerolysin in order to target and  kill 
immunosuppressive T regulatory cells that express the IL-2 receptor gene. This protein 
pro-toxin was shown to kill cells expressing IL-2R at low doses while having little to no 
effect on cells negative for this target. This chimera, known as IL2-R336A, depleted 
Tregs in both tumor bearing and non-tumor bearing mice. Mice given a GMCSF 
expressing CT-26 vaccine had reduced tumor growth when given IL2-R336A as an 
adjuvant. IL2-R336A also decreased tolerance to splenocytes expressing HA in 
transgenic mice with HA producing prostates. This suggests that this toxin may be a 
useful tool in enhancing the immune response against tumor antigens that would 
otherwise be tolerated. We propose that the use of this chimeric toxin and other agents 






Tumor targeting vaccines offer an attractive strategy as both a prophylactic in high risk 
patients and as a therapy to treat patients suffering from aggressive, therapy refractive 
cancer. Despite the large number of efforts to develop new immune based therapies, 
there are only two vaccines currently approved for the treatment of cancer and only one 
approved in the United States. This vaccine, Sipuleucel-T, is a protein vaccine using the 
prostate antigen Prostatic Acid Phosphatase and the patient’s own dendritic cells to 
systemically target metastatic tumors (1,2). While this therapy has been clinically 
validated to improve patient outcomes, the number of approved therapies is 
disproportionate with the amount of research done in this field.  This is likely due, at least 
in part, to the immuno-suppressive properties of the tumor microenvironment. Several 
groups have reported decreased T cell, dendritic cell, and Natural Killer cell activation in 
a variety of solid malignancies and that a higher immune cell count at time of diagnosis 
tends to correlate with better patient outcome (3,4). One mechanism of this inhibition is 
believed to be mediated through secretion of inhibitory cytokines by the tumor and 
stromal cells thus negatively regulated local immune cells (5). Another, more indirect 
mechanism, is the activation of regulatory immune cells in the tumor microenvironment 
that are able to potently suppress T cell activity thus promoting tolerance and overall 
tumor survival.  
Multiple cell subtypes are capable of locally inhibiting an anti-tumor response. These 
subtypes include Myeloid-derived suppressor cells (MDSCs), Mesenchymal stem cells, 
and T regulatory cells (Tregs) (5). Tregs, in particular, are characterized by being 
CD4⁺CD25⁺Foxp3⁺ and are potent regulators of local immune cell functionality (6). 
Modulation of T cell activity in the tumor microenvironment occurs through a plethora of 
mechanisms, many of which are not well understood. However, multiple cytokines 
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secreted by both tumor and stromal cells have been shown to be important for activating 
both of these subtypes including IL-6, IL-10, and TGF-β (7). It was shown by Hoelzinger 
et al. that disrupting IL-9 signaling inhibits Treg proliferation and Treg mediated 
immunosuppression (8) implicating the role of this pathway in promoting a tumor-tolerant 
phenotype by these cells. Recently, it has been shown that targeting 
immunosuppressive pathways can augment the immune system’s tolerance of a tumor 
in a clinical setting via the success of anti PD1 and PDL-1 antibodies (9, 10). Thus, 
specific targeting and depletion of Tregs and other suppressive cells in the tumor 
microenvironment could improve the potency of an anti-cancer vaccine or other immune 
based therapy and may be a useful therapeutic tool.   
Pro-aerolysin (PA) is an extremely potent protein toxin secreted by the pathogenic 
bacterium Aeromonas Hydrophila (IC50 < 100 pM against most cell-lines) (11). The toxin 
kills target cells via oligomeric pore formation in the target cell plasma membrane thus 
inducing osmotic lysis. PA is secreted in an inactive dimerized form that must be 
proteolytically activated on the C-terminus by the ubiquitously expressed enzyme furin or 
other trypsin like peptidases (12). In order to reach a sufficient concentration to 
oligomerize, the toxin must localize to the target cell membrane. PA accomplishes this 
by binding to GPI anchored membrane proteins via a membrane binding domain on the 
N-terminus of the toxin (13). The full mechanism of PA is depicted in Figure 1. Both 
properties of this toxin are crucial for its function, as perturbing either substantially raises 
the IC50 several orders of magnitude. Recently, we generated a mutant PA variant that 
was proteolytically activated specifically by the prostate specific protease PSA (14). This 
mutant killed PSA expressing cells both in vitro and in vivo and is currently in Phase III 
clinical trials for the treatment of Benign Prostate Hyperplasia. This work strongly 
suggests that PA mutants have the capability to be modified into cell specific targeting 
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agents despite having a relatively non-specific mechanism of activation. It also suggests 
that these PA variants have the capability of becoming useful therapeutics.  
Re-targeting PA is not limited to just modification of the C-terminal proteolytic activation 
site. Osusky et al. reported that a simple point mutation (R336A) can completely impede 
PA’s ability to bind to GPI anchors and thus localize to target cells (15). They then show 
that adding the cytokine IL-2 to the N-terminus of PA can rescue this capability and 
make PA toxic to only cells expressing the IL2 receptor (IL2R). This mutant (IL2-R336A) 
Figure 1: Cartoon depicting the mechanism of cell death induced by PA.  
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was not toxic to non-IL-2R expressing cells at any concentration tested. Therefore, it is 
reasonable to suggest that IL2-R336A could specifically and potently target IL-2R 
expressing cells in vivo and would have limited toxicity, if any, against all other cells.  
Because Tregs express IL-2R in reasonable quantities relative to other cells (16), we 
hypothesized that IL2-R336A could be used to deplete Tregs in vivo and potentially 
augment immune-based therapies in tumor bearing mice. In this study, we evaluate the 
potential of this strategy as an immuno-activator and vaccine adjuvant in mice.  
Materials and Methods  
Cell Lines  
All cell lines were from the American Type Culture Collection (Manassas, VA). The 
CTLL-2 mouse cell line was maintained in RPMI 1640 medium supplemented with 10% 
fetal bovine serum and 10% T-STIM with concanavalin A or with 100 units/ml of human 
recombinant IL2. The EL-4 mouse cell line was maintained in Dulbecco's modified 
Eagle's medium supplemented with 1 mM sodium pyruvate and 10% fetal bovine serum. 
The HuT-78 human cell line was maintained in Iscove's modified Dulbecco's medium 
supplemented with 20% fetal bovine serum. The PC3 cells were maintained in RPMI 
1640 medium supplemented with 10% fetal calf serum and 2 mm l-glutamine.  
Proaerolysin (PA) and IL2-R336A-PA proteins were provided by Dr. Buckley, University 
of Victoria and were generated as previously described (15). Unless otherwise specified 
all other reagents were from Sigma (St. Louis, MO). 
Effects of IL2-R336A on response to GVAX cell vaccine 
The mouse colorectal cancer cell line CT-26 cells were purchased from ATCC. CT-26 
cells secreting murine GM-CSF (GVAX) were generated as previously described (17).  
To assess direct effects on growth Balb-c mice were inoculated subcutaneously with 5 x 
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105 CT-26 cells on day -7.  On days -3, -2, and -1, mice received a single intravenous 
injection of 10µg/kg of IL2-R336A in sterile saline or saline vehicle. On day 0, Balb/c 
mice were immunized subcutaneously with vehicle or 106 irradiated (50Gy) CT26-GM-
CSF cells. Tumor volumes were measured serially.  For survival experiment, 40 mice 
were treated as described above with exception that mice received 2 injections of 5 x 
105  irradiated CT-26-GMCSF cells with one injection near axial lymph nodes and the 
second injection near inguinal lymph nodes. Animals were sacrificed by CO2 overdose 
when tumors reached 2cc in size. All animal experiments were conducted according to 
protocols approved by the Johns Hopkins University School of Medicine Animal Care 
and Use Committee. 
Treg Depletion 
Balb/c mice were implanted subcutaneously with 106 4T1-HA cells. Mice received a 
200µl intravenous injection with either 100 µg/ml (20 µg) PC61 anti-mouse CD25 
antibody (BD Pharmingen) (n=6) or 68 µg/mL (13.6 µg) IL2-R336A-PA (n=6) or no 
treatment control (n=7).  Blood was collected from the tail vein of each mouse 8 hours 
after injection.  Draining lymph nodes, spleens and tumor tissue was also obtained.  
Staining for CD4, CDC25, and FoxP3 expression was performed by as previously 
described by Leao et al (18). Antibodies to CD4 (Allophycocyanin-conjugated, APC) and 
CD25 (Biotin-conjugated, pure) were purchased from BD Pharmingen (La Jolla, CA, 
USA). PE-labeled Ab to Foxp3 was purchased from eBiosciences (San Diego, CA, 
USA), and intracellular staining was carried out according to the manufacturer's 
instructions. The secondary Ab for CD25 was Streptavidin-Alexa Fluor® 488 (Invitrogen, 
Carlsbad, CA, USA). The cells were stained and analyzed by FACScan (Becton 
Dickinson, Mountain View, CA, USA) using the CellQuest software. The acquired data 
were reanalyzed using the Flowjo software (Treestar, Inc., Ashland, OR, USA). 
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Vaccination studies.   
Transgenic mice expressing hemagglutinin antigen (HA) under the minimal rat Probasin 
promoter (−426 to +28 bp) in the prostate were provided by Dr. Drake and generated as 
previously described (19).  Vaccinia virus and Listeria Monocytogenes expressing HA 
were provided by Dr. Drake and generated as previously described (20, 21).  The 
recombinant vaccinia viruses were amplified in HuTK- cells, purified over 36% sucrose, 












Figure 2: Comparison of WT PA vs. IL2-R336A PA Schematic of WT PA (left) 
and the modified IL2-R336A (right) (A).  Table depicting the cell killing capabilities 




In order to specifically and potently target IL-2R positive Tregs, two modifications were 
made to WT PA (Figure 2A) as shown by Osusky et al. First, a single point mutation, 
R336A, was made in the membrane binding region of the protein in order to ablate GPI 
anchor binding and reduce toxicity against cells not expressing IL-2R. Second, 
recombinant IL-2 was fused to the N-terminus of PA in order rescue the toxin’s ability to 
localize to plasma membranes (Figure 2A). All  cell lines tested were very sensitive to 
lysis via WT PA as 1 nM of the toxin killed vast a majority of cells within an hour. 
However, the four cell lines not expressing the IL2 receptor were hardly affected with the 
same dose of IL2-R336A despite their inerrant PA sensitivity. The cell line, CTLL-2 was 
almost equally as sensitive to both pro-drugs with 1 nM of IL2-R336A killing 75% of the 
cells after only an hour (Figure 2B). It should be noted that CT26, the line used for GVAX 
experiments, was not particularly sensitive to IL2-R336A.  
To assess the in vivo effect of IL2-R336A, we measured Treg depletion in mice dosed 
with the toxin. Specifically, the ratio of Treg cells to non Treg cells (determined by flow 
cytometry) was used to quantify this effect. One dose of 400 μg/kg of the toxin reduced 
the peripheral Treg to non Treg ratio by 50% and 75% in non-tumor bearing and tumor 
bearing mice respectively (Figure 3A). Somewhat surprisingly, there was no difference in 
this ratio between tumor bearing and non-tumor mice that received no treatment. We 
then determined the dosage required to see such a depletion in draining lymph nodes. 
We injected mice with 1 or 3 doses (once per day) of IL2-R336A and measured the Treg 
to non Treg ratio after 24 hours. The effect generated by the drug was compared to an 
IL2R antibody to determine whether or not this depletion was due to specific PA 
mediated lysis or via perturbation of IL2 signaling. IL2R antibody treatment had no effect 
in Treg count after 24 hours compared with the control group. A single 400 μg/mL 
dosage of IL2_R336A also had no effect on this ratio in draining lymph nodes. However, 
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3 daily doses of the toxin depleted Tregs by 50% after 24 hours of the final dose (Figure 
3B). Based on this experiment, we used this dosing scheme for our GMCSF vaccine 
adjuvant studies.  
  
Figure 3: IL2-R336A depletes Tregs in tumor bearing mice. Peripheral Treg: 
Non Treg cell count of control animals (blue) or animals dosed with 400 ug/mL 
IL2-R336A (yellow) in tumor bearing vs non-tumor bearing mice (A). The same 
dose was given either once or three times for three days. Treg counts were 





If IL2-R336A can be used as a potent vaccine adjuvant, it must be able to improve the 
therapeutic response in vaccine model systems. In order to do this, we gave three daily 
doses (400 μg/kg) of IL2-R336A to Balb-c mice that were implanted with a CT-26 tumor 
4 days prior to the first injection. We then vaccinated the mice with a GMCSF expressing 
CT-26 tumor the day after the third injection of the toxin (Figure 4A). Relative tumor  
A 
Figure 4: IL2-R336A improves response in combination with GVAX therapy. 
Balb-c mice implanted with a CT26 tumor were dosed with 400μg/kg IL2-R336A 
or Vehicle three times on three consecutive days. On day 4, mice were given a 
GMCSF expressing irradiated CT26 tumor vaccine or the vehicle (A). Tumor 
measurements were made 10 days post vaccination and compared to the day 0 
starting volume (B). Survival of CT-26 xenograft mice dosed with CT-26 GVAX 
(black triangles), IL2-R336A (white circles), both agents (black squares) or 







volume (compared to the tumor volume the day of vaccination) was measured ten days 
afterwards. Mice given no treatment, the toxin itself, or the vaccine itself showed no 
significant change in relative tumor volume after ten days. Only mice given both the 
vaccine and the sequential doses of IL2-R336A showed a reduction in tumor growth. 
These mice had relative tumor volumes half that of the control mice after ten days. This 
difference was determined to be statistically significant with a p value less than 0.05 
(Figure 4B). We also assessed the survival (tumors greater than 2 cubic cm) of these 
treated animals. We saw no difference in survival between control animals, and animals 
dosed with CT-26 GVAX or IL2-R336A alone. We did, however, find that mice treated 
with combination of the vaccine and the toxin adjuvant had a slight survival advantage 
(not statistically significant), consistent with the decreased tumor size observed in these 
animals (Figure 4C).  
We then asked whether or not IL2-R336A could enhance the efficacy of a tumor vaccine 
against an antigen that was otherwise tolerated by T cells present in the tumor a 
common phenomenon in solid malignancies. We gave a single dose (400 μg/kg) of IL2-
R336A to Balb-c transgenic mice expressing hemagglutinin (HA) on their prostate gland. 
Two days later, we gave either a vaccine against HA expressing Vaccinia or HA 
expressing Listeria Monocytogenes. We then injected HA producing mouse splenocytes 
loaded with dye. We measured T cell mediated cytolysis and release of the dye using 
flow cytometry and measured vaccine efficacy as specific lysis of these splenocytes 
(Figure 5). Mice given no treatment or the toxin alone showed no specific lysis after 24 
hours. Mice given either the Vaccinia or Listeria vaccines alone showed modest 
amounts of specific lysis at this time point. When given in tandem with IL2-R336A, both 
groups receiving vaccines showed an increase in T cell mediated killing. Specifically, 
mice given the adjuvant and the Vaccinia vaccine had an approximate 10 fold increase 
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in specific lysis. Mice given the Listeria vaccine showed a more modest 50 % increase in 
specific lysis compared to the no adjuvant group. It should be noted that there was 




Figure 5: IL2-R336A reduces immune tolerance of HA-expressing splenocytes. A 
single 400 μg/kg dose of Il2-R336A was given to HA producing transgenic mice two 
days prior to administration of a Vaccinia (Vac) or Listeria Monocytogenes (LM) HA 
producing vaccine or the vehicle. On day 7, HA producing splenocytes loaded with dye 








We used a previously generated, mutant, chimeric toxin in order to disturb Treg function 
in immuno-competent mice and assessed the protein’s potential as a vaccine adjuvant. 
The protein, IL2-R336A, was shown by Osusky et al. to selectively and potently target 
IL-2R expressing cell lines while having no effect on IL-2R negative cell lines. We 
supplemented this finding by injecting R336A PA into mice and observed no toxicity at 
any dose tested (data not shown) despite using doses that are orders of magnitude 
higher than the therapeutic range of this protein. Both of these data suggest that R336A 
PA and mutants of this protein are safe to give at therapeutic doses without generating 
any acute toxicity and is suggestive that the R336A mutation substantially improved the 
therapeutic range of the protein.  
IL2-R336A, in vivo, was shown to deplete Tregs in peripheral blood after 24 hours with a 
single 400 μg/kg dose by 50% in both tumor bearing and non- tumor bearing mice 
suggesting the toxin is both potent and fast acting as the cell based assays would 
indicate. Three daily consecutive doses of the toxin depleted Tregs in draining lymph 
nodes 24 hours after the third dose was administered. An antibody against mouse IL-2R 
did not generate the same depletion of Tregs strongly suggesting that the depletion is a 
result of specific PA mediated killing as compared to modification of IL-2 signaling. Both 
experiments show a significant decrease in Tregs supporting the idea that IL-2R based 
targeting is a viable strategy depleting these cells in both the circulatory and lymphatic 
system. We did not examine the dosing regimen necessary to completely ablate Tregs 
as this may generate more unwanted autoimmune side effects due to decreased 
tolerance by the immune system. The optimal dose and Treg depletion level will still 
need to be determined in order to maximize effect and minimize unwanted toxicity.  
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Regardless, we then assessed whether depletion of Tregs through both tested 
regiments was sufficient to enhance the response of an immune based therapy. 
Because three doses of IL2-R336A  was enough to deplete Tregs by 50% in draining 
lymph nodes after a mere 24 hours, we used this dosing strategy to see if the toxin could 
enhance the effect of an anti-tumor vaccine in Balb-c mice. Neither GMCSF CT-26 
vaccine given nor the toxin given by itself had any effect on tumor growth, however, 
when given together, a significant reduction in tumor volume was seen after 10 days. 
Because the vaccine had no effect by itself, this experiment suggests that the presence 
of immuno-suppressive Treg cells in the stroma alone was enough to suppress any anti-
tumor T-cell activity. IL2-R336A was able to augment the GMCSF CT-26 vaccine, as 
tumor growth was slowed substantially 10 days post vaccination. This experiment, as a 
whole, demonstrates the large influence that Tregs play in the tumor microenvironment 
and that simply reducing the number of these cells is enough to reverse this effect and 
improve the efficacy of an immuno-therapy.  
One major obstacle facing any anti-cancer immune based therapy is the issue of 
tolerance, that is, the immune system’s inability to be activated by the presence of tumor 
antigens despite being exposed to them via a vaccination or by other means. To address 
this issue, we used a transgenic mouse line that has become tolerant to the HA antigen 
growing in the prostates of the animals. We then vaccinated the mice against HA and 
assessed whether or not IL2-R336A could augment the response to this antigen via 
injection of dye labeled, HA expressing splenocytes. Mice given both the toxin and an 
anti- HA Vaccinia vaccine had a staunch increase in HA specific targeting compared to 
mice only given the vaccine while mice given the toxin and a Listeria showed a modest 
increase in HA specific cell killing. The reason between this substantial difference is not 
entirely clear, however, it may be due to the natural difference in immunogenicity 
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between the two organisms used or the amount of HA produced by each vaccine. Again, 
because Tregs likely play a crucial role in promoting tolerance of host based antigens, it 
is unsurprising that selectively killing these cells would have a notable effect on vaccine 
efficacy. This experiment suggests that one dose of IL2-R336A can reduce the tolerance 
to an antigen of interest and help re-activate the local immune cells. This system, while 
artificial, demonstrates the therapeutic potential in targeting Treg cells for 
immunotherapy purposes and their overall influence in negatively regulating the immune 
system in the context of cancer. This finding has yet to be examined on tumor specific 
antigens in vivo.  
It is clear through this study and others that the presence of Tregs in the tumor 
microenvironment is one of the most important factors that determines the immune 
system’s ability to target neoplastic cells. Our IL-2R targeting pro-toxin IL2-R336A was 
able to both enhance the efficacy of a tumor-based vaccine and reduce tolerance to host 
derived antigen-based vaccines in immuno-competent mice. Further study must be done 
on how the quantity of the depletion of these cells correlates with the overall efficacy of a 
vaccine as well as the types of solid tumors that are most likely to benefit from a Treg 
targeting agent. Because IL2-R336A was able to augment vaccine efficacy in vivo and 
be given safely at therapeutic doses, we propose that the usage of this toxin as a tumor 
vaccine adjuvant warrants further study in other malignancies and animal models. We 
also advocate for the usage of other, similar strategies to target immuno-suppressive cell 
types in the tumor stroma. It is not unreasonable that given the success observed with 
IL2-R336A that other targeting moieties such as growth factors and scFv fragments 
could be fused to this mutant toxin in order to generate novel pro-drugs capable of 
targeting both  tumor cells directly and pro-tumor stromal cells. We are optimistic about 
the therapeutic and biochemical power this protein offers and the possible ways it could 
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Chapter 2: PLGA Microparticle Encapsulation of a Novel Prostate-Targeted 
Biologic For Tumor Delivery: Characterization of Release and Functionality 
 
As the fields of therapeutics, pharmacology, and biotechnology continue to advance, 
more and more biologic-based agents are evaluated pre-clinically for their potential as 
therapeutic and diagnostic agents. While many of these agents will see success in such 
studies, others will ultimately fail due to a plethora of reasons. Agents that do not 
effectively reach their target tissue in pre-clinical and clinical studies usually do not 
advance further despite highly targeted and specific mechanisms of action. Targeted 
delivery of the biologic agent in question, however, could possibly circumvent these 
problems and improve the agent’s pharmacologic profile. In this study, we evaluate one 
such approach, PLGA micro-particle encapsulation, in order to improve the systemic 
administration of a promising prostate-selective pro-toxin known as PRX302. PRX302 is 
a mutant bacterial toxin selectively activated by the prostate-specific peptidase PSA. 
Due to specific interactions with cell surfaces, this toxin cannot be delivered systemically 
in a safe manner. Currently, PRX302 is being evaluated for its potential as a locally 
administered treatment for benign prostate hyperplasia, however, due to its highly 
specific and potent mechanism of action, its use as a systemic prostate cancer 
therapeutic is enticing. Because of its interesting mechanism of action, delivering 
PRX302 to a target tissue via PLGA microparticles may facilitate this protein as a useful 
anti-cancer therapeutic. In order to explore this hypothesis, we enveloped PRX302 in 
PLGA micro-particles and examined its release and functionality using a home-made 
sandwich ELISA and cell based-cytotoxicity assays. The mutant pro-toxin was 
successfully encapsulated in these micro-particles and released in an aqueous 
environment. Quantitative release kinetic studies indicated that, after 10 days at 37 
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degrees, roughly 90 ng (10% total PRX loaded) of detectable material was released. 
This material, when incubated with enzymatically active PSA or cells expressing 
functional PSA, was cytotoxic to human cells. These results suggest that PRX302 can 
be successfully loaded into PLGA micro-particles and released slowly into the local 
micro-environment, however, the kinetics of this release may not be ideal depending on 
the desired concentration. The assay and methods described will facilitate future studies 
examining the controlled release of this protein using other PLGA formulations or other 
delivery platforms and suggest that this method of drug encapsulation may help 






The use of biologics for treating human disease has risen dramatically in the past two 
decades. These agents can offer unique mechanisms of action and selectively not 
possible with small molecule-based pharmacophores. In the field of oncology alone, 
there are currently over a dozen monoclonal antibodies approved to treat both solid and 
liquid malignancies (1). The selective toxicity induced by these antibodies can often 
combine synergistically with radiation therapy, chemotherapy, or immune-based therapy. 
Given the modest success of these agents and the plethora of tumor-selective targets 
available, it is reasonable to expect the surge in biologic-based therapy  to continue.  
 
Unfortunately, undesirable pharmacokinetic properties of many of these agents have 
resulted in poor clinical trial performances and failure of the drug to ever be utilized for 
clinical purposes. Rather than leave these candidates to anecdote, re-targeting them 
using an alternative delivery platform may salvage their potential. This can be done 
using a variety of methods including controlled release via poly-lactic-glycolic acid 
(PLGA) micro-particles, a hydrophilic polymer capable of ensnaring both small molecule 
drugs and biologics, which slowly degrade via acid-catalyzed hydrolysis (2,3). PLGA 
microparticle encapsulation has some success in the context of cancer. PLGA micro-
particles loaded with nafarelin (a GnRH agnostic) were shown to slowly release the 
peptide systemically and suppress testosterone production via GnRH axis feedback 
inhibition (4). It is evident that the pharmacokinetic and pharmacodynamics properties of 
macromolecules can be augmented using controlled release-based approaches which 
can yield desired effects that would be otherwise impossible using standard systemic 




Biologics that interact with cell surfaces or that are taken up non-specially may benefit 
from encapsulation provided that the loaded microspheres can be delivered to the tumor 
microenvironment efficiently using an appropriate vector. It is evident that unique 
aspects of the tumor-microenvironment facilitate cell-specific migrations that can be 
used for therapeutic purposes. It has been well established that, as a mechanism for 
suppressing the local immune response, prostate cancer cells recruit mesenchymal 
stem cells (MSCs) to the surrounding stroma via paracrine signaling (5). MSC’s are a 
multipotent stem cell lineage capable of differentiating into a variety of cell types 
including osteocytes and adipocytes. Several studies have associated MSCs with the 
tumor micro-environment and their role in creating a pro-tumor stromal environment 
(6,7). Interestingly, MSCs have been shown to efficiently phagocytize PLGA micro-
particles while maintaining viability and cell function (8). For these reasons, it is rational 
to predict that PLGA-loaded MSCs could facilitate the selective delivery of biologic-
loaded microparticles with robust cell-targeting potential. Ideally, such a biologic agent 
would already display the ability to potently kill cancer cells in vitro and in vivo.  
Pro-aerolysin (PA) is an attractive target for such a strategy. PA is a secreted bacterial 
toxin from the species Aeromonas Hydrophila which induces cell lysis via oligomeric 
channels formed in the target cell membrane (9). To regulate this function, PA requires 
specific proteolysis on its C-terminus to remove a small inhibitory peptide via the 
protease furin (10). In order to target the protein to prostate cancer cells, Williams et al 
mutated the native furin activation sequence to a peptide capable of being selectively 
activated by the Prostate Specific Antigen (PSA), a chymotrypsin-like serine protease 
which  has been shown to be only functional in the stroma of normal and malignant 
prostate epithelial cells (11, 12,13). The mutant, known as PRX302, was only functional 
in the presence of enzymatically active PSA (13). PRX302 was shown to be selectively 
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toxic at picomolar doses to cell lines that produced sufficient amounts of functional PSA. 
Intratumoral injections of PRX302 yielded a robust regression in tumor size in PSA 
expressing xenografts. Unfortunately, due to PRX302’s capability of localizing to cell 
membranes via binding to GPI-anchored proteins (14), it has poor bioavailability and 
cannot be distributed systemically in the body. Because, PRX302 was able to induce 
rampant cell death when locally injected into tumors, it is currently being evaluated in 
Phase III clinical trials for the treatment of Benign Prostate Hyperplasia (BPH) (15).  
Thus, in order to harness the potent and selective power of PRX302 for systemic cancer 
therapy, PRX302 must be delivered selectively to the tumor micro-environment.  
 
It is for these reasons that our lab proposes to load PLGA microspheres with PRX302 as 
a cargo for MSC-facilitated targeted delivery. We have successfully delivered prostate-
targeted pro-drugs previously for similar purposes. The PSA-activated thapsigargin 
analog G114 has been shown to be efficiently loaded and released from this material 
(16). This platform would take advantage of PRX302’s ability to potently and externally 
lyse cancer and stromal cells while being selective for cells expressing PSA as well as 
MSC’s ability to selectively localize in this same micro-environment. In order to assess 
the potential of this multi-armed approach, it is best to characterize the pro-toxin’s 
functionality and release from these PLGA microspheres independent of the cell-based 
uptake. In this study, we develop a sensitive and accurate assay using two PRX302 
antibodies, HG6 (monoclonal) and MPC (polyclonal), to characterize the release of this 
pro-toxin from loaded PLGA-microspheres and assess the functional capacity of this 
drug once it has been released using cell-based methods. 
Materials and Methods 
Materials and reagents 
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All reagents were purchased from Sigma Aldrich unless stated otherwise. Recombinant 
PRX302 protein and polyclonal MPC antibody were a gift from the laboratory of Peter 
Howard. These reagents were generated as previously described. Materials utilized for 
MP generation are as previously described (15). Human erythrocytes were obtained 
from discarded clinical specimens in accordance with IRB-approved protocols. All 
prostate-cancer cell lines were obtained from the American Type Culture Collection.  
HG6 Monoclonal Antibody Generation 
The HG6 hybridoma was maintained in DMEM supplemented with 10% FBS, 1mM 
sodium pyruvate, 1% pen/strep, 1% L-glutamine, and 0.1% 2-mercaptoethanol at 37C in 
a humidified incubator with 5% CO2. Prior to media conditioning, cells were slowly 
adapted to 5% IgG-stripped FBS followed by expansion of the culture to the desired 
volume. Media was then conditioned for 1wk prior to collection of supernatant, 
centrifugation to remove cell debris, and passed through a 0.2um filter. 
Supernatants were concentrated to less than a milliliter using Amicon Ultra-15 
Centrifugal Filter Units (10k MWCO) (UFC903024) according to manufacturer’s 
instructions. HG6-containing media was then incubated with Protein G Agarose (Pierce 
20398), washed, and eluted according to manufacturer’s recommendations. IgG positive 
fractions were tracked using absorbance at 280 nm. Pooled fractions were then dialyzed 
vs 1 L TBS (pH = 7.4) for 2 hours  and 2 L TBS overnight at four degrees Celsius. Final 
protein concentration was determined using absorbance at 280 nm with a molar 
extinction coefficient of 150,000 L mol-1 cm-1 
PRX302 Sandwich ELISA Optimization 
In order to develop the appropriate conditions for an accurate, robust, and reproducible 
sandwich ELISA, optimal detection and capture antibody conditions were evaluated. To 
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do this, we coated Nunc-Immuno micro well plates (Sigma  M9410) with various 
concentrations of HG6 mouse monoclonal IgG in PBS pH = 7.4 and incubated this 
overnight, at room temperature, shaking, and protected from ambient light. The next day, 
all coating solution is removed and the plate is blocked with 300 uL of a 1% BSA solution 
in PBS incubated at RT for one hour shaking. All samples of PRX302 were diluted in 
blocking solution at least one hundred fold. Samples were incubated with coated plates 
for 2 hours at RT shaking. The plate was then washed three times with 300 uL of a 
solution of PBS containing 0.05% Tween20 and dried via dabbing. The MPC polyclonal 
rabbit antibody was then diluted at various concentrations in blocking solution and 
incubated in the same manner as the PRX samples. Prior to detection of the MPC 
antibody, the plate was washed three times and dried. A solution of anti-rabbit HRP-
conjugated IgG (Cell Signaling 7074S) was then diluted 1:5000 in blocking buffer and 
incubated with the plate for one hour at RT shaking. The plate was then washed three 
times and incubated with a 1 mg/mL solution of ABTS substrate (Sigma 10102946001 
ROCHE) in peroxide buffer (Sigma 11204530001 ROCHE). The reaction was then 
incubated 1 hour at RT while protected from ambient light. After incubation, the plate 
was read at both 410 and 570 nm with the final value being the difference between the 
two wavelengths.   
Sandwich ELISA for Assay Validation and Release Studies 
Based on the optimization studies, it was determined that the optimal concentrations for 
the capture and detection antibodies were 4 ug/mL and 5.5 ug/mL respectively. The 
protocol for all ELISA-based assays in this study is identical to the optimization work 
using these concentrations. For the parallelism and spike/recovery experiments, all 
samples were diluted in PBS (pH = 7.4) containing 1% BSA. To assess the effects of cell 
culture media (RPMI 1640 w/ 10% FBS) and human plasma (isolated from whole blood) 
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on the assay, PRX302 was diluted to 500 ng/mL in 100% whole media and plasma and 
further diluted 5 fold serially in sample buffer. Once the assay was completed, the 
respective points were superimposed on the standard curve based on their theoretical 
concentration and actual obtained A450-A570 value. For samples with unknown PRX 
values, we plotted the obtained A450-A570 and the theoretical concentration 
independent of the standard curve. To determine actual PRX302 concentration, we used 
a 4-parameteter non-linear regression and calculated the concentration using the same 
wavelength pair.  
Hemolytic PRX302 Functional Assay 
To characterize the functional parameters of PRX302 and validate the ELISA 
measurements independently, we used an erythrocyte-based hemoglobin release assay. 
Isolation of human erythrocytes (RBCs) from whole blood was done so by spinning down 
vials of donated blood at 800 x g for 15 minutes. The supernatant containing plasma was 
saved and the buffy coat was discarded. An aliquot of RBCs was taken and diluted to 
4% in normal saline. This solution was spun to remove dead or damaged cells at 1000 x 
g for 5 minutes. RBCs were then washed once more in saline. Dilutions of PRX302 or 
unknown samples were made in PBS with BSA after being incubated with human PSA 
(Bio Rad 7820-0504) for two hours at 37 degrees Celsius. These solutions were then 
mixed with the washed 4% RBC solution and incubated for 2 hours at 37 degrees while 
rotating. Samples were then centrifuged at 1000 x g for 5 minutes in order remove intact 
RBCs. The supernatant was then transferred to a 96 well plate and read at 540 nm. The 
samples were then plotted as a function of percent hemolysis when compared to RBCs 
incubated with 2% Triton X100. The standard curve generated was then used to either 
show parallelism or determine the concentration of functional PRX from unknown 
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samples. For the most accurate calculations, samples were diluted so the A540 would 
correspond to the linear portion of the standard curve.  
PRX302 PLGA Microparticle Generation  
PRX302 MP generation was performed using a double immersion protocol. This was 
done via the same preparatory steps as the prostate-targeting pro-drug G114 in previous 
studies (15). Physical characteristics of these MPs were determined as previously 
described. Total protein loaded was determined by 280 UV spectroscopy.  
PRX302 PLGA Release Assay  
To accurately determine the release rates for various formulations of PRX302 MPs, we 
used the previously discussed PRX302 quantitative sandwich ELISA protocol. 
Lyophilized PRX microparticles were washed twice in saline containing 1% BSA for 5 
minutes each and resuspended in this solution a concentration of 1 mg particles per mL 
of solution. The solution was sonicated on the lowest power for 10 seconds, three times, 
on ice and then incubated at 37 degrees shaking for various time points. To harvest the 
resulting supernatants and MP pellets, the suspension was centrifuged for 15 minutes at 
800 x g with the resulting 0.5 mL supernatants and pellets being stored at -80 degrees 
Celsius until needed. Supernatants were diluted in ELISA sample buffer at several 
dilutions in order to obtain concentrations appropriate for the dynamic portion of the 
standard curve.  
Tissue Culture Experiments & Cell Viability  
PSA-expressing LNCaP cells and PSA-null DU145 cells were cultured in RPMI 1640 
containing 10% FBS and supplemental L-glutamine. For incubations with PRX302 MP 
supernatant, LNCaPs were plated at 5000 cells per well and DU145 cells were plated at 
1000 cells per well. PRX302 MP supernatant was then diluted serially directly into each 
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well and incubated for 48 hours. Cell morphology was monitored regularly using a light 
microscope. To directly measure cell viability, we performed the MTT assay. To do this, 
we removed 100 uL of media and supplemented each well with 15 uL of MTT dye 
directly. The cells were then incubated for 4 hours at 37 degrees. Cells were then lysed 
and the metabolized MTT dye was solubilized using 100 uL of stop solution. The plate 
was then incubated at room temperature for at least an hour and then read using A570-
A650. A standard curve was used to determine the exact number of cells in each well as 
opposed to just reporting absorbance.  
Results 
To accurately determine how much PRX302 was released from the loaded PLGA MPs in 
terms of both concentration and as a percentage of total cargo loaded, it is essential that 
a sensitive, quantitative, and robust assay be used. To assess the viability of a sandwich 
ELISA using the HG6 and MPC antibodies as such an assay, we performed an 
optimization experiment using increasing concentrations of both. We also required this 
assay to have minimal background in biologically relevant samples to avoid issues 
related to the signal to noise ratio. Based on our optimization grid, higher concentrations 
of both HG6 and MPC increased the signal robustly while yielding very minute changes 
in the background (Figure 1A) suggesting that this antibody pair was appropriate for the 
development of this assay.  
Quantitatively, we observed a robust and saturated increase signal in both capture and 
detection antibody (Figure 1B and 1C) as PRX302 concentrations increased. The 
capture antibody titration experiment (Figure 1B) showed an increase in the range of the 
assay in between 2 and 4 ug/mL and no change between 4 and 8 ug/mL. In order to 
determine the saturating concentration range for the detection antibody, we used at least 
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a 5 fold increase in concentration compared to the optimization grid. Similar to the 
capture antibody, we observed an increase in the range of the assay as concentrations  
 
increased until the signal saturated in between 5.5 ug/mL and 11.1 ug/mL.  For both 
optimization experiments, we observed a linear increase in signal in between 0 and 10 
ng/mL with the signal saturating in between 10 and 50 ng/mL and continuing to do so 
between 50 and 100 ug/mL. For the comprehensive standard curve, we used 4 ug/mL 
Figure 1: PRX302 Sandwich ELISA Development. Optimization plate for 
PRX302 ELISA. Concentrations of monoclonal HG6 (capture), polyclonal MPC 
(detection), and PRX302 standard  at three concentrations (A). Effect of varying 
concentrations of capture antibody concentrations at 2 (black), 4 (red), and 8 
(blue) ug/mL (B). Effect of varying concentrations of detection antibody 
concentrations at 2.7 (black), 5.5 (red), and 11.1 (blue) ug/mL (C). 
Comprehensive standard curve at concentrations ranging from 0.003 to 500 
ng/mL (D). All values are represented as A410-A570.  
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capture antibody and 5.5 ug/mL detection antibody to maximize the dynamic range of 
the assay while minimizing the amount of each reagent used. The standard curve of this 
assay had a linear range typically in between 10 and 100 ng/mL and achieves saturating 
signal above 100 ng/mL (Figure 1D). Graphing the standard curve as a 4 parameter 
curve yields a sigmoidal curve that “flattens” below 10 ng/mL and above 100 ng/mL. The 
limit of detection for this assay, based on the standard curve, was approximately 1 
ng/mL PRX302.  
 
Figure 2: PRX302 Sandwich ELISA Validation. PRX302 standard curve  
(black) with independent parallel samples  superimposed onto the curve 
(red) (A). PRX302 standard curve with independent  parallel samples diluted 
in whole human plasma (blue) and serum-containing RMPI (B). Standard 
curve of a functional assay developed  to independently validate PRX 
ELISA.. Independent points (red) were diluted and overlaid to show 
parallelism (C). Direct comparison of samples measured by PRX ELISA and 
functional hemolysis assay (D).   
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Typically, to validate an ELISA assay for a given analyte, independent samples of a 
known concentration are plotted on a standard curve generated on the same plate in 
order to show parallelism. We chose to dilute PRX302 1:2 from a starting concentration 
of 50 ng/mL, representing a large portion of the linear, and most dynamic range of our 
curve (Figure 2A). All points were superimposable on the curve with the exception of the 
50 ng/mL dilution. In addition to assessing how independent samples in assay buffer 
behave, we performed a ‘spike, recovery’ assay in which PRX302 was diluted to a 
known concentration in either RPMI containing 10% FBS or 100% human plasma. This 
assay can be used to also determine if certain biological sample sources contain 
components that interfere with the assay’s validity and at what concentration these 
effects can be mitigated. We observed almost no interference in the samples originally 
diluted in RPMI, as only the top 500 ng/mL point deviated from the standard curve 
(Figure 2B). All further dilutions (1:5 serially) were superimposable on the curve. For 
samples diluted in human plasma, there was a substantial decrease in signal observed 
in all dilutions above 1:125, as these samples had a dynamic range of approximately 
80% of the standard curve.  
Because our ELISA assay determines the concentration of total PRX302 in a solution 
and not functional drug, we used a hemolytic titer-based assay to calculate how much 
released pro-toxin was actually capable of killing cells. Briefly, this assay measures the 
release of hemoglobin from lysed erythrocytes in solution and, like the ELISA, is 
compared to a standard curve of known, fully functional PRX302. In this standard curve, 
we observe a 4 parameter sigmoidal relationship between the concentration of PRX302 
in ng/mL and the percentage of total lysed erythrocytes compared to a detergent control 
(Figure 2C). The obtained standard curve had a limit of detection of approximately 100 
ng/mL and was linear from 300 to 1000 ng/mL. Like the ELISA, we took independent 
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samples of known concentration and plotted it on our standard curve to show 
parallelism. All diluted samples were superimposable on the standard curve within the 
standard error. We then plotted samples which were diluted 1:2 from 500 ng/mL and 
calculated using the ELISA and hemolytic assays independently in order to compare 
them directly. When plotted, we observe a linear relationship between each sample set 
on each assay with a slope of 0.83. (Figure 2D). The hemolytic assay deviated from the 
trend at the lowest sample which had a concentration of 62.5 ng/mL.  
Figure 3: Characterization of PRX302 PLGA MPs.  Electron micrograph of G114 
loaded PLGA MPs from Levy et al. (A). Table depicting the properties of PRX302-
loaded MPs (B). Release of PRX302 from 1 mg/mL MPs in solution over 2 days 
represented as % of total cargo released (D). Red blood cell lysis assay of either 
PRX302 alone or PRX302 MP supernatants with (grey) or without (black) PSA 
present (D). Viability of LNCaP (E) or DU145 (F) cells incubated for 48 hours with or 
without PRX302 MP supernatant and with (grey) or without (black) PSA.  
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We successfully encapsulated PRX302 into PLGA microspheres using the protocol as 
shown by Levy et al to encapsulate the pro-drug G114 in these polymers. Based off this 
study in which those MPs were of similar size, we expect the PRX302 loaded 
microspheres to physically resemble the G114 loaded material (Figure 3A). These MPs 
had an average size of roughly 1-2 microns and a loading efficiency of 7.1% (Figure 3B). 
Following two, five minute washes in saline, we observe roughly 10% of encapsulated 
PRX302 released over a period of 48 hours (Figure 3C) which seems to have plateaued 
as compared to the initial release kinetics over the first few hours. Released PRX302 MP 
supernatant lysed red blood cells to a similar degree as PRX302 diluted to the same 
concentration of 50 nM (concentration of supernatant determined from the ELISA) after 2 
hours (Figure 3D). This supernatant, when diluted to a concentration of approximately 10 
nM, killed LNCaP prostate cancer cells regardless of the presence of PSA (Figure 3E) 
while only affecting DU145 cells in the presence of PSA as measured by the MTT assay 
(Figure 3F).  
Discussion 
The major goal of this study is to develop a series of methods to assess the release of 
PRX302, a novel prostate targeted biologic pro-drug, from PLGA microspheres. In order 
to fully characterize the release and functionality of the molecule, we have developed 
two different bioassays to both determine the concentration of total and functional 
PRX302. The former assay, a homemade sandwich ELISA, utilized a monoclonal mouse 
antibody, deemed HG6, as a capture antibody and a rabbit polyclonal antibody, deemed 
MPC, as a detection antibody. We performed a series of optimization experiments in 
order to fully maximize the signal to noise ratio of this assay and to minimize reagent 
use. As the concentration of both antibody increased, we observed a robust increase in 
the dynamic range of the assay which eventually saturated. Based on these 
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experiments, we opted to use a concentration of 4 ug/mL HG6 and 5.5 ug/mL MPC. 
These concentrations were selected specifically due to the large dynamic range 
achieved while utilizing the smallest amount of material possible. The assay itself had a 
very robust signal to noise ratio with a linear range that spanned roughly an order of 
magnitude of PRX302 concentrations. All PRX302-containing samples in this study were 
diluted such that the concentration would fall in this range of the standard curve, thus 
ensuring for the most accurate determination of concentration possible. The other assay, 
a hemolytic functional assay, also allowed for the accurate determination of functional 
PRX302 in solution, however, this assay was much less sensitive and depended on the 
sample containing functional drug.  
Before using our ELISA to determine the concentration of PRX302 released into 
solution, we validated this method via showing sample parallelism in a variety of 
biological samples. Specifically, samples were diluted to known concentrations in assay 
diluent, media with 10% FBS, and human plasma. Samples diluted in PBS with BSA and 
plotted onto the standard curve independently were mostly superimposable on the curve 
suggesting the assay is internally reproducible. Very little change in signal was observed 
in media with FBS suggesting the components of the solution are compatible with the 
assay and a dilution of 5 fold or more in assay buffer is suitable. We observed a 
substantial drop in signal when plasma was used. This is to be expected given the much 
higher concentration of total protein and other biological components that could interfere 
with the assay. We observe an accurate measurement of PRX302 in human plasma 
after a 125 fold dilution of the sample suggesting the responsible components that 
interfere with this assay are at a concentration compatible with accurate measurement of 
the pro-drug concentration at this concentration. We recommend that all samples that 
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are obtained from mammalian samples such as whole blood or plasma be diluted at 
least 125 fold in sample buffer in order for any measurements to be reliable.  
We next validated our functional assay and compared it directly to the ELISA. This assay 
utilized the lysis of living, intact, human red blood cells and measured the release of 
soluble hemoglobin into the supernatant. By using a dose response curve of PRX302 vs 
total lysis, we can accurately and independently measure the concentration of this drug 
as a function of cell lysis and assess how much released PRX302 is functional. Red 
blood cells were selected for this assay as they are incapable of repairing aerolysin-
induced plasma membrane damage and their release of a robust chromophore upon 
lysing. As we increased PRX302 concentration in this experiment, we observed a 
saturable dose-dependent increase in RBC lysis with an EC50 of approximately 500 
ng/mL (10 nM) PRX302 after a 2 hour pre-incubation with PSA and a 2 hour exposure to 
the erythrocytes. This assay had a limit of detection of roughly 100 ng/mL PRX302 
which, in comparison with the sandwich ELISA, is much less sensitive despite being 
simpler and more direct. When compared directly with the ELISA, we observed a linear 
relationship of samples above 100 ng/mL strongly suggesting that the hemolysis assay 
is capable of accurately measuring total protein assuming 100% of the protein is 
functional. This result also validates the hypothesis that the sandwich ELISA is capable 
of detecting all functional PRX302 in a sample. This side by side comparison will allow 
us to quantitate how much of the PRX302 protein is capable of killing PSA-expressing 
cells once released from the PLGA MPs.  
We were pleased to trivially produce microspheres loaded with purified PRX302. These 
particles, being roughly 1-2 microns in diameter on average, are the desirable size for 
MSC internalization based on previously characterized properties of cell uptake (8, 17). 
The release of this material from these particles was then tracked over the course of 48 
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hours in which we observed roughly 10% of the protein cargo loaded was released into 
the supernatant. These rates are comparable to other proteins loaded in PLGA MPs and 
suggest that PRX302 can be used in this platform with relative ease. We were also 
pleased to observe that our assay was predictive of the concentration of PRX302, as our 
expected concentration of PRX302 determined by the ELISA was consistent with the 
published functional concentrations of this molecule on erythrocytes as well as LNCaP 
and DU145 prostate cancer cells. Released PRX302 also had no activity on RBCs until 
PSA was present strongly suggesting that the material released was completely intact, 
contained its C-terminal inhibitory piece, and would be non-toxic to cells not producing 
PSA in vivo. Because we did not observe the  same amount of lysis as PRX302 at the 
same protein concentration, we expect that some portion  of released material was not 
fully functional possibly due to aggregation or denaturing of the protein upon release.  
On LNCaP prostate cancer cells that produce some enzymatically active PSA in vitro, 
PRX302 MP supernatant grossly affected viability regardless or not if PSA was 
exogenously added suggesting that the PSA secreted by these cells activated the toxin 
enough  to be functional. For the DU145 cells, we did observe some toxicity of the 
supernatant when no PSA was present. This suggests that, because DU145s do not 
produce any PSA, other proteases present on the cells were able to process the toxin 
and activate it to a degree. While surprising, PRX302 was shown to be functional at 
higher doses on non-PSA producing cells likely for this reason (13). Regardless, we 
were encouraged to see that PRX302, following release from these microspheres, was 
toxic to different cell lines in a PSA-specific manner and released from the microparticles 
at reasonable rates.  
This work demonstrates two successful proofs of principles. The first is the development 
of a sensitive and robust biochemical assay to accurately detect the release of a novel 
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prostate-targeted biologic from PLGA microspheres. This tool will allow us to further 
develop other novel therapeutic platforms using this protein, study its pharmacokinetic 
properties further in vivo, and further improve on our loaded microparticle design and 
optimization. Second, we were able to show PRX302 being released from these 
particles at reasonable concentrations over a period of time consistent with their 
internalization into MSCs and that this pro-drug retained a majority of its activity and still 
required proteolytic processing and activation in order to be cytotoxic. Now that this 
system has been developed and the necessary assays optimized, we can further utilize 
this strategy to determine its potential as a novel and effective method to selectively 
deliver pro-drugs to prostate-derived tumors for therapeutic purposes.  This work also 
demonstrates a methodical approach to developing a therapeutic platform and 
understanding the intricacies to novel technologies used to address human health-
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Chapter 3: PSA-Activated Serine Proteases as a Novel Therapeutic Strategy to 
Target Prostate Cancer 
Abstract:  
Prostate cancer is the most diagnosed malignancy in American men and the second 
leading cause of cancer-related death. Patients succumbing to the disease primarily 
suffer from metastatic cancers as opposed to localized disease. Currently, treatments for 
metastatic prostate cancer are largely palliative and fail to substantially improve patient 
lifespan. Thus, new innovative therapies are needed to target metastatic tumors. 
Prostate Specific Antigen (PSA) is a chymotrypsin-like serine protease secreted by both 
normal and cancerous prostate epithelial cells. Our lab has characterized PSA’s 
enzymatic activity to be specific for the stroma of tumors despite reasonable 
concentrations in circulation. PSA is, therefore, an attractive target for cancer-selective 
cytotoxic therapy due to its localized activity and unique substrate profile. Because a 
vast majority of prostate cancer cells grow slowly and exist in the G0 stage of the cell 
cycle at any given point, a proliferation-independent cytotoxic payload is preferred in this 
strategy. Recently, it was shown that the human protease Granzyme B (GZMB), at low 
micromolar concentrations, can cleave an array of extracellular matrix (ECM) proteins 
thus perturbing cell growth, signaling, motility, and integrity. It is also well established 
that other human proteases such as trypsin can induce similar effects. Because both 
enzymes require N-terminal proteolytic activation to be functional, we propose to 
synthesize and characterize PSA-activated zymogen mutants capable of being 
selectively activated in the tumor stroma and targeting these effects to prostate-derived 
tumors. In this study, we examine the enzymatic and cell targeting parameters of these 
drugs, described as EK-PSA-TRP and EK-PSA-GZMB. These pro-enzymes were 
activated robustly by PSA and induced ECM damage to cancer cells in vitro thus 
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Every year, more than 220,000 American men are diagnosed with prostate cancer. 
Despite notable success in managing patients with localized disease, 30,000 men will 
ultimately succumb to prostate cancer this year (1). A vast majority of these patients 
suffered from metastatic tumors as opposed to lesions located in the prostate 
exclusively. These tumors are usually resistant to most chemotherapeutic therapies and 
are able to evade the immune system following administration of therapy.  Because 
metastatic prostate cancer (MPC) therapies only provide temporary relief from disease 
burden, it is vital that new, innovative therapeutic strategies are developed to combat 
this malignancy as stand-alone and adjuvant therapies.  
 
Prostate-based malignancies are among the slowest growing of the solid tumors. 
Because a vast majority of tumor cells exist in the G0 phase of the cell cycle, traditional 
proliferation-dependent cytotoxic chemotherapy remains ineffective. Though docetaxel is 
currently approved to treat metastatic prostate cancer, it’s mechanism of action depends 
on inhibiting localization of the Androgen Receptor via binding to microtubules (2). It is, 
therefore, essential that novel therapeutic strategies kill metastatic tumors in a 
proliferation-independent manner. Because most cytotoxic agents capable of killing non-
proliferating cells are globally toxic to most tissue, converting these agents into 
therapeutics is dependent on the ability to regulate their activity to the tumor 
microenvironment.  
Prostate-specific Antigen (PSA) is a secreted chymotrypsin-like serine protease 
expressed by both cancerous and non-cancerous prostate epithelial cells (3,4). PSA, 
most notably, has been characterized as a marker for prostate cancer progression due 
to its presence in the bloodstream in patients with viable tumors. Despite this, PSA is not 
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enzymatically active in the bloodstream of patients with localized or distal disease due to 
the presence of the serum protease inhibitors α-1-antichymotrypsin and α-2-
macrglobulin which form covalent complexes with the enzyme (5, 6).  Because of PSA’s 
high expression and enzymatic activity in the stroma of prostate-derived tumors, 
including MPC, and the fact that it is rapidly inactivated in the bloodstream, PSA is an 
attractive target for a pro-drug based therapeutic strategy in which a proliferation-
independent cytotoxin would be cleaved and activated selectively in the extracellular 
space of a tumor cell. One major benefit to this strategy is that not every cell in the 
microenvironment would need to express PSA in order to be targeted. This, so called, 
“field effect” is an interesting principle for MPC therapeutic strategies, as the pro-drug 
agent would target a highly heterogeneous tumor microenvironment and not only kill 
tumor cells but adjacent tumor-supporting stromal cells. In order to design efficient and 
selective protein and peptide sequences for PSA, our lab characterized PSA’s ability to 
cleave various florescent substrates vs. other common proteases in circulation. This 
study showed that selective, efficiently-hydrolyzed substrates can be generated and that 
PSA prefers peptide substrates varying from four to seven amino acids in length that 
contain at least one serine upstream of the cleavage site (7). Given this substrate profile, 
our lab has generated several PSA-activated pro-drugs that kill cells only in the 
presence of enzymatically active PSA.  
 
Granzyme B (GZMB), like PSA, is a secreted serine protease expressed by activated 
Cytotoxic T-Lymphocytes (CTLs) (8). When co-secreted into the immune synapse along 
with pore-forming proteins such as perforin, GZMB can translocate into the target cell 
cytoplasm, cleave and activate pro-apoptotic factors, and induce target cell death. 
Intracellular-substrates of GZMB include members of the caspase family, ICAD, BCL-2 
and related proteins, and several pro-mitotic factors (9).  Recently, GZMB was shown to 
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be able to degrade various components of the extracellular matrix (ECM) at high-
nanomolar concentrations (10, 11, 12). This extra-cellular mechanism of GZMB was 
shown to induce anoikis of surrounding cells, decrease cell motility, and even potentially 
act as a pro-inflammatory cytokine. Interestingly, GZMB has been shown to be resistant 
to inhibition by protease inhibitors in serum suggesting it has long-acting effects in vivo 
(13).  Upon trafficking to the secretory granule of the CTL, GZMB must be cleaved and 
activated on the N-terminus by Cathepsin C in order to be functional (14, 15). Another 
human protease, cationic trypsin (TRP), has been well characterized to cleave ECM 
components at similar doses as GZMB. TRP, also like GZMB, is expressed in an 
inactive confirmation with a N-terminal pro-piece, DDDDK, a substrate for the activating 
protease, enterokinase (EK) (16, 17). Because both GZMB and TRP have extracellular 
effects on human cells in vitro and have well characterized pro-forms activated by serine 
proteases, they are interesting candidates as potential prostate-targeting PSA-activated 
pro-drugs.  
 
Recently, a method of mammalian-based expression system for human GZMB was 
established. Gerhmann et al. developed a rapid, efficient system in which GZMB can be 
expressed in milligram quantities by transiently transfecting HEK-293T cells. In order to 
minimize toxicity to cells expressing the protein, GZMB was expressed with a non-native 
enterokinase (EK) substrate (DDDDK) immediately upstream of Isoleucine 1 (the first AA 
of active GZMB) (18). This yielded an EK-activated GZMB mutant which was 
catalytically nonfunctional until incubation with active EK enzyme. Based on this work, 
we hypothesized that the insertion of a high-efficiency PSA substrate between I1 of 
GZMB and the EK peptide would yield an efficiently-cleaved PSA-activated mutant (EK-
PSA-GZMB). Because human trypsinogen 1 (TRP) is non-specifically toxic to most cell 
types and is natively activated by EK on its N-terminus, we also postulated that using 
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this strategy would also yield an efficiently-cleaved PSA-activated mutant of trypsinogen 
(EK-PSA-TRP). In this study, we evaluate the enzymologic and pharmacologic 
properties of both PSA-activated proteins in vitro.   
Materials and Methods 
Design of PSA-activated GZMB and TRP proteins 
 
In order to synthesize constructs for both PSA-activated proteins, careful consideration 
should be made as to the locus of the PSA substrate and the substrate itself. Because 
serine protease perturbation of ECM proteins requires higher concentrations of active 
Figure 1: Schematic of EK-PSA-GZMB and EK-PSA-TRP pro-drugs. 
Mutations made to convert EK-activated GZMB into a PSA-activated zymogen 
(left) and WT Trypsin into a PSA-activated zymogen (right) 
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enzyme, we chose the efficiently-cleaved, less specific PSA substrate KGISSQY. This 
peptide was inserted in between the inhibitory  EK peptide DDDDK and the N-terminal 
Isoleucine residue of both proteins. Thus, hydrolysis by PSA of either EK-PSA-GZMB or 
EK-PSA-TRP by PSA would yield exclusively the active GZMB and TRP enzymes. For 
EK-PSA-GZMB a chemically conjugatable mutant containing a C-terminal reactive 
cysteine was used should a targeting moiety need to be added to enhance toxicity of the 
protein. This mutant had no effect on GZMB expression or catalytic activity (data not 
shown).  Because EK natively activates TRP, we chose to leave the native APF 
tripeptide as the N-terminus of EK-PSA-TRP. Figure 1 depicts this strategy.  
 
Cloning and mutagenesis of GZMB and TRP constructs 
In order to express hGZMB in reasonable amounts using a mammalian expression 
system, the EK-C248 gene was first constructed. To do this, the WT GZMB gene 
(Origene Plasmid SC321693) was amplified out of the respective vector, altered to 
contain the C-terminal cysteine, and flanked with EcoR1 restriction site and upstream 
vector sequence with the primer set F: 
CAGTGTGGTGGAATTCATGCAACCAATCCTGCTTC R: 
GATATCTGCAGAATTCTTAGTAGCGTTTCATGGTTTT. PCR was run using Accuprime 
Pfx Supermix (Thermo 12344-040) enzyme mix and run according to manufacturer’s 
instructions with a Tm of 53°C. PCR product was purified on a 1.5% agarose gel after 
running at 100V for 45 minutes, excised, and isolated using a NucleoSpin Gel and PCR 
clean up kit (Machery-Nagel 740609). For transient expression in HEK-293T cells, WT 
GZMB-C248 (Eco R1) was inserted into the vector pcDNA 3.1 (+)  (Thermo V790-20) 
using an InFusion HD Cloning kit (CloneTech 638909). The resulting gene-containing 
plasmid insert was then transformed into Stellar Competent E. Coli (CloneTech  636763) 
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according to manufacturer’s instructions. Colonies were picked, grown in 5mL LB 
containing 100 μg/mL Ampicillin for 8 hours, and expanded in 50mL LB containing 100 
μg/mL. WT GZMB (pcDNA 3.1) was isolated using a PureLink® HiPure Plasmid 
Maxiprep Kit (K2100-06). DNA sequencing was performed using Sanger sequencing (T7 
sequencing primer) via the Johns Hopkins Sequencing and Synthesis facility.  
Because WT GZMB is toxic to HEK-293T cells, the protein must be expressed in an 
inactive conformation capable of being rapidly activated via proteolysis once expressed. 
For this reason, the native GE inhibitory di-peptide was replaced by an enterokinase 
cleavage site (as seen above). To mutate this cleavage site, GZMB-C248 (pcDNA3.1) 
was added to a Q5 Site Directed Mutagenesis (NEB E0554S) kit containing the primers 
F: CGACAAAATCATCGGGGGACATGAGG R: 
TCGTCGTCTGCATCTGCCCTGGGCAG. The reaction was run according to 
manufacturer’s instructions with a Tm of 67°C and an extension time of 210 seconds. 
PCR product from this reaction was confirmed on a 1.5% agarose gel, ligated using the 
Q5 kit KLD enzyme mix, and transformed into NEB5α E. Coli according to 
manufacturer’s instructions. EK-C248 (pcDNA3.1) was amplified, purified, and 
sequenced as described above. To convert this protein into a PSA-activated pro-drug, 
the PSA substrate KGISSQY was inserted between the DDDDK EK peptide and the 
active sequence of GZMB. Using the mutagenesis primers F: 
CTCTCAGTACATCATCGGGGGACATGAG R: 
GAGATTCCTTTTTTGTCGTCGTCGTCTGC, the plasmid EK-PSA-GZMB (pcDNA 3.1) 
was generated using the aforementioned mutagenesis protocol with a Tm of 64°C. The 
plasmid was amplified, harvested, and sequenced as mentioned above. In order to make 
a mutant lacking the DDDDK piece but with a PSA substrate on the N-terminus (PSA-
GZMB), we utilized the above mutagenesis protocol (EK-C248 pcDNA3.1 as a template) 
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with the primer set F: AGGAATCTCCTCTCAGTACATCATCGGGGGACATGAGG R: 
TTATGATGATGATGATGATGTGCATCTGCCCTGGGCAG with a Tm of 67 degrees 
Celsius.  
To generate a plasmid containing the human PRSS1 gene containing the KGISSQY 
PSA substrate and a hexa-histidine purification tag, we first cloned the PRSS1 gene into 
pcDNA3.1. Using the InFusion protocol described above, we inserted flanking Eco RI 
restriction sites on the ends of the human PRSS1 gene (human cationic trypsin) (Human 
PRSS1 natural ORF mammalian expression plasmid, Sino Biological, HG10816-CH) 
using the primer set F:  CAGTGTGGTGGAATTCATGAATCCACTCCTGATCC R: 
GATATCTGCAGAATTCTTAGCTATTGGCAGCTATGG and a Tm of 52 degrees Celsius 
and an extension time of 210 seconds while following the recommended InFusion 
cloning protocol. Plasmid was transformed, grown, and harvested as described above. 
Next, we performed mutagenesis using the NEB method above in order to insert the 
KGISSQY sequence and a C-terminal Histidine tag. To insert the PSA sequence, the 
primer set F:  CTCTCAGTACATCGTTGGGGGCTACAAC R: 
GAGATTCCTTTCTTGTCATCATCATCAAAGGG was used with a melting temperature 
of 61 degrees Celsius. For the mutagenesis respective to the Histidine tag, the set F: 
CACCACCATTAAGAATTCTGCAGATATCCAG  R: 
GTGATGATGGCTATTGGCAGCTATGGTG and a Tm of 60 degrees Celsius was used. 
Lastly, to make a TRP mutant lacking the native EK piece but containing a PSA 
activation sequence (PSA-TRP) we mutagenized the EK-PSA-TRP pcDNA3.1 plasmid 
by deleting the DDDDK peptide. This was done using the primer set F: 
AAAGGAATCTCCTCTCAGTACATC R: AGCAAGAGCAGCTGCCAC with a Tm 64 
degree Celsius. Like the GZMB constructs, all TRP mutants were sequenced using the 
Sanger method following isolation of the plasmid using a T7 promoter primer.  
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Expression of recombinant proteins in HEK293T cells 
HEK293T cells (ATCC® CRL-3216) were grown in DMEM w/ high glucose, 10% Fetal 
Bovine Serum, and supplemental L-glutamine. For all constructs, 5 x 106 cells were 
plated in multiple T75 flasks and incubated for 48 hours at 37°C. To transiently transfect 
cultures, 25 μg of cDNA (per flask) was added to 1.2mL of OPTI-MEM low-serum media 
and mixed with 74 μL of FuGENE HD (Promega E2311). This mix was incubated for 10 
minutes at room temperature, added to 20mL of DMEM media per T7, and incubated on 
cells overnight. To simplify the purification process, transfected cells were then washed 
once with 1X PBS (pH=7.4) and given serum-free, phenol-free DMEM w/ high glucose 
and L-glutamine. Cells were then incubated for at least 3 days. Supernatant was 
harvested before cell viability and attachment was compromised.  
Purification of recombinant GZMB and TRP proteins 
Once supernatant from transiently transfected HEK cells was collected, cell debris was 
removed from via centrifugation at 8000 x g for 10 minutes. The clarified media was then 
concentrated 20-fold using Amicon Ultra Centrifugation Filters (UFC901008) and mixed 
1:1 with 1X PBS (pH = 7.4). For GZMB-based pro-drugs (including PSA-GZMB to keep 
impurities consistent), a cation exchange resin (Fractogel EMD SO3
- Millipore 116882) 
was used to isolate the protein. Because GZMB has an unusually high pI of 9.5, the 
protein will bind a negatively charged column at a higher affinity at pH 7.4. For TRP 
based constructs, a Histidine binding Nickel resin was used (His-Select Ni Affinity Resin, 
Sigma P6611 ). The immobilized proteins were then washed with either 5mL of PBS or 
PBS containing 20mM Imidazole respectively three times. GZMB and TRP pro-drugs 
were then eluted using PBS containing either 1M NaCl or 300mM Imidazole 
respectively. Protein elution was tracked during this process using UV spectroscopy at 
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280 nm. Both constructs were then dialyzed to remove the components of the elution 
buffer and other small molecule contaminants. This was done by adding pooled fractions 
to a Slide-a-Lyzer Dialysis Cassette (MWCO 7K) (87722/87723) and dialyzing vs. PBS 
or PBS containing 1mM CaCl2 respectively. Dialyses were done at 500 fold excess 
volume and 1000 fold excess volume for 4 hours and 24 hours respectively. Final protein 
concentrations were determined using A280.  
 
PSA Activation and Protease assays 
In order to assess PSA’s ability to cleave, and activate both pro-drugs, both zymogen 
proteins were incubated with purified PSA (ABD Serotec 7820-0504). Specifically, PSA 
was added to a solution of EK-PSA-GZMB or EK-PSA-TRP in PBS to a final 
concentration of 0.01 mg/mL. This concentration was decided based upon the 
physiological concentrations of PSA in the prostate stroma determined by Denmeade 
et.al (5). All incubations were done at 37°C for the indicated time points. For Michaelis-
Menten experiments, pre-incubations of EK-PSA-GZMB and EK-PSA-TRP with PSA 
were done overnight and 4 hours respectively.  
 
In order to determine the enzymatic activity of GZMB and TRP-based constructs, 
specific peptide-based assays were used. For GZMB, a florescent based GZMB assay 
kit (Biovision K168-100) was used. The substrate, IETD-AFC, was diluted in assay buffer 
according to instructions and incubated with GZMB-containing samples for one hour at 
37°C. Fluorescence was measured at 380 nm excitation and 500 nm emission 
wavelengths. Concentrations of AFC released were based off a standard curve of diluted 
AFC.  For Michaelis-Menten kinetics of GZMB, a chromogenic substrate was used to 
measure catalytic activity of the protein. Specifically, Ac-IETD-pNA (AG Scientific G-
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1085) was diluted in DMSO to a stock concentration of 25 mM and diluted to various 
concentrations. EK-PSA-GZMB solution was then added 1:1 and read at 405nm at 
various time points. For EK-PSA-TRP activity and kinetic experiments, z-GPR-pNA 
(Sigma C2276) was diluted in DMF to a concentration of 2 mM (for activity experiments) 
and mixed 1:1 with protein solutions or diluted several fold for Michaelis-Menten 
experiments. Solutions were read at 405nm after 15 min for activity assays and at 
various time points to determine kinetic parameters. For all assays, the extinction 
coefficient 13500 M-1cm-1 L was used to determine the concentration of released pNA. 
All readings were corrected to background florescence/absorbance. Activity readings are 
represented as amount of substrate process per minute per mg of enzyme added.  
 
SDS PAGE and Western Blot Analysis 
In order to confirm recombinant proteins were correctly sized, SDS PAGE was 
performed using a BioRad gel electrophoresis system. Samples containing recombinant 
EK-PSA-GZMB/TRP proteins were mixed 1:1 with 4X reducing SDS PAGE Sample 
Buffer and boiled for 5 minutes. Samples were then loaded and run at 150V until fully 
migrated. For protein staining, the gel was then washed 2-3 times with RO H2O and 
stained for one hour with SimplyBlue Safe Stain solution (Thermo LC6060). To de-stain 
samples were washed in RO H2O overnight. For Western Blotting, samples were run on 
a non-reducing gel and were transferred to PVDF Immuno-Blot membrane (BioRad 
1620177) for 1 hour at 100V and incubated for one hour in TBST containing 5% milk. To 
monitor removal of the DDDDK peptide, an anti-DDDDK polyclonal antibody (Abcam 
1162) was diluted to 1:5000 in TBST/milk and incubated with the membrane overnight at 
4°C. The next day, the membrane was washed 5X with TBST and incubated with an 
anti-rabbit HRP-linked IgG (Cell Signaling #70762) diluted at 1:10000 in TBST/milk for 
one hour at 4°C. The blot was then washed 5X with TBST and incubated with 
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chemiluminescent substrate solution (Thermo 34077) diluted according to 
manufacturer’s instructions. The blots were then developed at specified time points via 
an X-ray film processor.  
Edman Degradation of EK-PSA-GZMB 
In order to demonstrate site-specific cleavage and activation of EK-PSA-GZMB by PSA, 
EK-PSA-GZMB was treated with plus PSA or buffer as described above overnight at 
37°C. Both samples were then run on an SDS PAGE gel and transferred  to a PVDF 
membrane as described above. The blot was then dried at room temperature for an hour 
and stained with SimplyBlue stain to visualize proteins. Sample was then de-stained 
using a solution of methanol (40% v/v) and acetic acid (10% v/v). Bands corresponding 
to the molecular weight of EK-PSA-GZMB were cut and stored in 1.7mL microfuge 
tubes. Edman degradation was performed by the Johns Hopkins Sequencing and 
Synthesis facility. Analysis was done on the three most N-terminal amino acids for each 
sample.  
Cell Culture, Viability, and Microscopy Experiments 
All prostate cancer cells and stromal cell lines were grown in RPMI 1640 medium 
containing 10% FBS and supplemental L-glutamine. Because bovine serum protease 
inhibitors slow the activity of PSA and TRP in vitro, all experiments were done in serum-
free conditions. In order to facilitate these conditions and maintain cell viability and 
growth, LNCaPs, and CWR22 Rv1 were plated on a 96 well plate pre-coated with  FBS 
(100μL RPMI with 10% serum per well for 4 hours at 37°C) in phenol-free, serum-free 
RPMI 1640 with L-glutamine and B27 serum supplement (Thermo 17504). Cells were 
plated at 5000 cells per well unless stated otherwise. The next day, cells were treated 
with either 3000 or 500 nM of EK-PSA-GZMB and EK-PSA-TRP plus or minus PSA at a 
final concentration 0.005 mg/mL unless stated otherwise. Cells not treated with 
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recombinant protein were treated with the respective dialysis buffer. Cells were 
incubated until visual effects were prevalent or for 7 days at 37 degrees. For GZMB-
attachment experiments, medium plus or minus 10% FBS and plus or minus 1μM 
GZMB. Solutions were then removed and cells were then plated in serum-free RPMI 
containing B27 and allowed to attach for 48 hours. To count the cells, the MTT assay 
was used. Specifically, 15μL of CellTiter 96 dye (Promega G4000) was added to each 
wells and incubated at 37°C for 4 hours. Stop solution was then added to each well at a 
volume of 100μL. Cells were then shaken for at least an hour at room temperature. The 
assay was read as the difference between absorbances at 570 and 650 nm. Cell number 
was calculated based off a standard curve for each cell line. To demonstrate altered cell 
morphology, cells were photographed using a Nikon TE200 fluorescence microscope 




Figure 2 Cloning and Expression of PSA-Activated TRP and GZMB. 
Sanger DNA sequencing results of the mutated N-terminus of both  EK-
PSA-TRP (A) and EK-PSA-GZMB (C) genes. CBB-stained reducing SDS-
PAGE gels with EK-PSA-TRP (B) and EK-PSA-GZMB (D).   
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To ensure all pro-drug enzymes were mutated correctly, we performed Sanger 
sequencing on both the PSA-activated TRP and GZMB genes. DNA sequencing 
analysis confirmed that both proteins contained an inserted KGISSQY PSA cut site 
immediately flanked by their respective catalytic domains and the inhibitory EK peptide 
(Figure 2A & 2C). For both mutants lacking their respective EK peptides, Sanger 
sequencing showed the successful removal of these residues thus yielding N-termini 
beginning with the KGISSQY substrate (data not shown). SDS PAGE analysis showed 
that both protein constructs were relatively pure following extraction from cell 
supernatant and further purification. EK-PSA-TRP protein when run under reducing 
conditions yielded two bands at 25 and 28 kDa (Figure 2B) while the GZMB mutant ran 
as a single band at 28 kDa (Figure 2D). Under non-reducing conditions EK-PSA-GZMB 
will run as both a monomer and a di-sulfide linked dimer (data not shown). Average yield 
was approximately 0.25 mg of EK-PSA-GZMB and 0.05 mg per flask of cells. It should 
also be noted that we obtained much lower expression yields for both PSA-activated 
protease mutants lacking the EK piece (referred to as PSA-TRP and PSA-GZMB). 
Yields did not improve when using NiNTA chromatography on PSA-GZMB despite it 
being cloned with a N-terminal His tag.  
Following expression, harvesting, and NiNTA purification, we examined the enzymatic 
characteristics of the EK-PSA-TRP protein. Using a trypsin-specific chromogenic assay, 
we pre-incubated the drug plus or minus enzymatically active PSA. Both PSA and EK-
PSA-TRP alone were unable to cleave the GPR-pNA substrate. Once pre-incubated 
together, we observed a steady increase in hydrolysis that stabilized after roughly 4 
hours (Figure 3A). Western blotting of these mixtures using an antibody specific for the 
enterokinase substrate peptide on the N-terminus showed the uncleaved protein 
(running at both 25 and 28 kDa) with no PSA present. This signal was removed after a 4 
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hour incubation with PSA (Figure 3B). Using the GPR-pNA release assay, we assessed 
the stability of this drug after a 4 hour pre-incubation with PSA. We observe no 
substantial loss of activity after a 23 day incubation at 37 degrees Celsius compared with 
Day 0 (Figure 3C). Velocity experiments confirmed that the active EK-PSA-TRP mutant 
displays classical Michaelis-Menten enzyme kinetics with linear changes in velocity 
below 500 uM substrate (Figure 3D). While there is some baseline activity of EK-PSA-
TRP the Vmax between the PSA-treated and non-treated differ by almost 120-fold while 
the Km values were not notably different (Figure 3E).  
Figure 3: EK-PSA-TRP is a PSA-activated Trypsin mutant. Enzymatic hydrolysis 
of GPR-pNA by EK-PSA-TRP (red), PSA, (blue), and EK-PSA-TRP mixed with PSA 
(purple) pre-incubated for various times (A). Western blot analysis of EK-PSA-TRP 
+/- PSA probed with an anti-DDDDK rabbit polyclonal antibody (B). Enzymatic 
activity of EK-PSA-TRP incubated for 0 or 23 days at 37 degrees after being pre-
exposed to PSA (C). Michaelis-Menten enzyme kinetics of EK-PSA-TRP (black) or 
EK-PSA-TRP with PSA (red) (D). Calculated enzymatic parameters of inactive and 




Like the EK-PSA-TRP protein, we also aimed to evaluate the enzymatic activity of EK-
PSA-GZMB in terms of activation kinetics, stability, and catalytic kinetics. Using a 
florescent substrate for GZMB, IETD-AFC, we assessed the activity of EK-PSA-GZMB 
with or without PSA pre-treatment following various pre-incubation times. Similar to the 
EK-PSA-TRP, the EK-PSA-GZMB had very low to no activity in this assay as well as the 
Figure 4: EK-GZMB-GZMB is a PSA-activated Granzyme B mutant. Enzymatic 
hydrolysis of  IETD-AFC by EK-PSA-GZMB (red), PSA (blue), and EK-PSA-TRP 
mixed with PSA (purple) pre-incubated for various times (A). Western blot analysis 
of EK-PSA-GZMB +/- PSA probed with an anti-DDDDK rabbit polyclonal antibody 
(B). Enzymatic activity of EK-PSA-GZMB incubated for 23 days  at 37 degrees 
after being pre-exposed to PSA (C). Michaelis-Menten enzyme kinetics of EK-
PSA-GZMB (black) or EK-PSA-TRP with PSA (red) (D). Calculated enzymatic 
parameters of inactive and activated EK-PSA-GZMB (E).  
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sample containing PSA by itself (Figure 4A). However, PSA-treated EK-PSA-GZMB 
showed robust enzymatic processing of the substrate which seemed to plateau at 24  
hours. Western Blotting the PSA treated EK-PSA-GZMB reactions using non-reducing 
conditions showed a decrease on both monomer and dimer bands of the protein with a 
vast majority of the signal removed after 24 hours (Figure 4B). Stability studies of 
activated EK-PSA-GZMB showed that like the EK-PSA-TRP protein, the enzyme 
retained most of its activity after 23 days at 37 degrees (Figure 4C). Following an 
overnight incubation with PSA, we observed an obvious difference in the baseline Vmax 
Figure 5: The N-terminal EK piece both stabilizes and inhibits EK-PSA-
TRP and EK-PSA-GZMB. Enzymatic activity of pre-incubated EK-PSA-TRP + 
PSA (red dashed), PSA-TRP + PSA (black dashed), EK-PSA-TRP alone (red 
solid), and PSA-TRP alone (black solid) (A). Enzymatic activity of EK-PSA-
TRP +/- a 4 hour EK treatment (B). Enzymatic activity of pre-incubated EK-
PSA-GZMB + PSA (red dashed), PSA-GZMB + PSA (black dashed), EK-PSA-
GZMB alone (red solid), and PSA-GZMB alone (black solid) (C). Enzymatic 
activity of EK-PSA-GZMB +/- a 4 hour EK treatment (D).  
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of the “inactive” EK-PSA-GZMB as opposed to the sample treated with PSA for the 
substrate IETD-pNA. Like EK-PSA-TRP, the enzyme’s linear change in velocity was 
observed at concentrations less than 0.5mM substrate. When comparing the baseline 
inactive species and the species that was incubated with PSA, we see a 30 fold increase 
in Vmax with relatively no difference in Km (Figure 4E). To confirm PSA cleavage was 
occurring at the desired locus on the protein, we isolated digested EK-PSA-GZMB and 
performed Edman degradation. N-terminal analysis of the protein confirmed that the 
residues I-I-G were the first three amino acids of the protein (data not shown) consistent 
with that of the active enzyme.  
 
Figure 6: EK-PSA-TRP inhibits LNCaP cell growth selectively in the 
presence of PSA. Light microscopy images of LNCaP cells treated +/- 
500 nM  EK-PSA-TRP and +/- PSA at 10X magnification (A). MTT 
assay of LNCaP  (B) or DU145 (C) cells treated with PSA (black), EK-
PSA-TRP (grey) or both (red) for 7 days.  
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In order to more completely understand the mechanism behind the mutations made to 
modify the zymogen activation of TRP and GZMB, we removed the EK piece from each 
protein (native TRP and EK-GZMB) and inserted the PSA-activated substrate KGISSQY 
yielding mutants deemed PSA-TRP and PSA-GZMB. Activation kinetic assays with PSA-
TRP and EK-PSA-TRP showed activation of both proteins following a four hour PSA 
incubation, however, EK-PSA-TRP was approximately 4 fold more active when 
comparing the specific activity (Figure 5A). For EK-PSA-GZMB and PSA-GZMB we 
observed a similar trend, in that the mutant containing the EK piece was robustly more 
active than the mutant lacking it (Figure 5A & 5C). In the case of GZMB, the PSA-GZMB 
species had no detectable activity compared to the somewhat active PSA-TRP. Both 
Figure 7: EK-PSA-GZMB inhibits cell growth selectively in the presence of 
PSA. Light microscopy images of LNCaP cells treated +/- 3 uM EK-PSA-GZMB and 
+/- PSA at 10X magnification (A). MTT assay of LNCaP (B), DU145 (C), CWR22 
Rv1 (D), or human prostate stromal cells (E) treated with either PSA (black bars), 
EK-PSA-GZMB (grey bars), or both (red bars) for 7 or 9  days.   
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EK-PSA-TRP and EK-PSA-GZMB proteins, when treated with porcine EK at 5 EU/mL 
were both robustly active after a four hour incubation (Figure 5B & 5D). Both active 
enzymes had a higher specific activity following incubation with EK than with PSA.  
 
In order to accurately mimic the prostate cancer microenvironment and evaluate any 
effect these proteins have on cell growth, we plated various cell types on plastic tissue 
culture plates pre-treated with media containing 10% serum. The cells were then allowed 
to attach to the dish and remain viable in media lacking serum protease inhibitors that 
would otherwise disrupt PSA’s ability to activate these drugs. EK-PSA-TRP at 0.5 uM 
was treated on LNCaP cells plus or minus exogenously added PSA. Cells treated with 
the vehicle alone grew slower than under normal conditions but were otherwise healthy 
and viable (Figure 6A). LNCaP cells exposed to either PSA alone or EK-PSA-TRP alone 
were unaffected. However, when both were co-incubated on cells, we observe gross 
morphology and violent aggregation consistent with how LNCaPs grow with no ECM 
present (Figure 6A). Using the MTT assay and a LNCaP standard curve, we were able 
to quantitate the cell number for each treated group. Over the period of 5 days, we 
observe that both groups treated with EK-PSA-TRP or PSA alone doubled in cell count 
which was not substantially different from the control cells. LNCaP cells affected by 
activated TRP digestion of the ECM did not grow at all, as number of cells plated and 
counted cells were identical. This difference in cell number was found to be statistically 
significant (p < 0.05). This experiment was repeated on DU145 (Figure 6C) but no 
notable differences in morphology or cell growth between treated and untreated cells 
was observed.  
We performed the same set of experiments to assess EK-PSA-GZMB’s ability to inhibit 
the growth of prostate cancer cells and if the toxicity was limited to just LNCaP cells. For 
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the light microscopy experiment, we observed, again, no effect of the cells treated with 
EK-PSA-GZMB or PSA alone. In combination, 3 uM EK-PSA-GZMB activated by PSA 
induced obvious morphology changes and clumping of affected cells (Figure 7A). To 
further understand these effects kinetically, we used time lapse microscopy and 
observed that a majority of the clumping occurs within 24 hours of treatment with the 
activated GZMB protein (data not shown). Like the EK-PSA-TRP drug, these effects 
correlated with a significantly significant difference in growth, with cells treated with PSA 
and EK-PSA-GZMB not appearing to grow when compared to controls and the starting 
number of cells plated on Day 0 (Figure 7B). Unlike the EK-PSA-TRP protein, however, 
we did observe both a morphological and anti-proliferative effect on DU145, CWR22 
Rv1, and stromal cells. When treated with PSA or EK-PSA-GZMB alone, no 
morphological differences were observed on any of these cells. PSA-treated EK-PSA-
GZMB induced cell aggregation, morphological changes and differences in cell adhesion 
to the plate (data not shown). Like the LNCaPs treated with EK-PSA-GZMB, we observe 
a growth inhibitory effect on each cell line when compared with the respective controls 
on DU145, CWR22 Rv1, and human prostate stromal cells( Figure 7C, 7D and 7E) with 
statistically significant differences being observed in the DU145s and stromal cells. 
Interestingly, GZMB at this dose induced morphological effects on PC3 and LAPC4 cells 
but no changes in cell count was seen (data not shown).  
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Because we observed notable effects on cell morphology and growth which strongly 
correlated with enzymatic activity of these drugs, we aimed to examine whether these 
effects were driven by protease-induced ECM damage. To do this, we pre-coated a plate 
with serum free media, media containing 10% serum, or media with serum and 1 uM 
GZMB. We then removed the solutions and plated LNCaPs and CWR22 Rv1 cells in 
serum free media and incubated them for 48 hours. Cells plated on surfaces coated with 
media attached well, had normal morphology, and proliferated (Figure 8A). Cells plated 
in serum free wells did not attach but appeared to grow at rates comparable to the 
control. Both LNCaPs and CWR22 Rv1 cells plated on wells treated with serum and 
Figure 8: GZMB induces prostate cancer cell growth inhibition via 
damage to the ECM. Light microscopy images of LNCaP (top) and CWR22 
Rv1 (bottom) were plated in serum free RPMI (B27 supplemented). in wells 
treated with buffer (left), media-containing serum (middle) or media with serum 
and 1 uM GZMB (right) and incubated for 48 hours at 37 degrees. 
Magnification is 10X (A). Quantitation of plated LNCaP (left) and CWR22 Rv1 
(right)  48 hours after plating (B).   
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GZMB displayed morphology similar to those treated with activated EK-PSA-GZMB and 
did not grow as well when quantitated with the MTT assay (Figure 8B). Only the growth 
of the LNCaP cells were significantly affected by the GZMB treated matrix while the 
CWR22 Rv1 cells were not despite the obvious visual effects.   
 
Discussion 
It has been reported in the literature that human cancer cells in vitro can be targeted via 
disruption of their interactions with the ECM. This is an attractive mode of therapeutic 
targeting as it affects the entire tumor and not just cells expressing a specific marker. 
Because our lab has examined the potential role of proteases in cancer chemotherapy, 
we opted to explore the idea of using human proteases as an agent capable of 
damaging the tumor ECM. In order to hone this potential route of toxicity to the tumor 
microenvironment and limit the effects on normal tissue, we sought to engineer these 
proteases into zymogen mutants capable of being activated selectively by PSA. To 
achieve this, we chose to modulate the zymogen activation of human TRP, as it has 
been well established to digest components of the ECM and has a well characterized 
zymogen activation. Our mutant, EK-PSA-TRP, contained a robustly cleaved PSA 
substrate, KGISSQY flanked by the inhibitory EK substrate and the rest of the enzyme. 
This protein was successfully expressed in mammalian tissues, albeit at rather low 
levels due to toxic effects observed on the HEK293T cells. Following purification, SDS 
PAGE showed that this species runs as two bands, likely a post translational 
modification, as both were cleaved by PSA and were isolated using NiNTA agarose and, 
therefore, not a proteolytic fragment on either terminus. We also chose human GZMB as 
a second candidate due to its published ability to digest the ECM, to be expressed as a 
zymogen with an EK piece on the N-terminus, and to resist inhibition via serum protease 
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inhibitors. This protein was easily expressed in mammalian cells and ran as a single 
band on a protein gel.  
We have successfully engineered both human TRP and GZMB to be activated by PSA. 
Incubation experiments with PSA using a TRP and GZMB specific substrate has shown 
that both mutants, EK-PSA-TRP and EK-PSA-GZMB, remain inactive until incubated 
with PSA. Interestingly, we observe very different activation kinetics of both drugs based 
on the plateau of the enzymatic assay and the immunoblots probing with an anti-DDDDK 
antibody. Because the TRP zymogen was activated at least 5 times faster than the 
GZMB, it suggests the PSA substrate was presented in a more favorable conformation 
on the TRP pro-drug possibly due to the EK piece already being in a more native 
orientation. Both pro-drugs showed less activity per mg enzyme than their EK-activated 
counterparts suggesting that the PSA substrate peptide affects the folding of the 
enzymes negatively. We were, however, pleased to see that both enzymes retained a 
majority of their initial activity following a 23 day incubation at 37 degrees Celsius 
suggesting their stability would not be a limitation for use as an in vivo therapy. We were 
also pleased to see the robust difference in Vmax values for both enzymes compared to 
their zymogen counterparts while seeing very little change in Km suggesting that PSA 
activation and removal of the EK inhibitory piece induced a conformational change in the 
zymogen that increased enzymatic turnover as opposed to changing substrate binding. 
Edman degradation analysis also strongly suggests that the PSA cleavage occurred 
specifically in between the C-terminal tyrosine residue of the PSA substrate and the N-
terminal isoleucine of GZMB, as intended.  
The simple insertion of the KGISSQY PSA substrate into the native TRP and EK-GZMB 
proteins to yield a PSA-activated mutant was unprecedentedly simple. We chose to 
further delve into the role of both peptides (DDDDK and KGISSQY) in yielding such a 
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mutant given that EK-GZMB and   WT TRP have already been established as EK 
activated zymogens. To do this, we designed two more mutants containing only the 
KGISSQY substrate on the N-termini of TRP and GZMB deemed PSA-TRP and PSA-
GZMB respectively. We then expressed these mutants in mammalian tissues and used 
the same chromatography methods as the EK-containing proteins. It should be noted 
that, in terms of expression, both PSA-GZMB and PSA-TRP expressed at much lower 
levels than the EK-containing PSA-activated variants suggesting that the EK piece 
promotes proper folding and expression of these enzymes. Furthermore, PSA-TRP and 
PSA-GZMB had substantially less activity when incubated with PSA at the same length 
as EK-PSA-TRP and EK-PSA-GZMB with PSA-GZMB having no detectable activity after 
a 4 hour incubation with PSA. This also indicates that the EK piece plays a role in the 
proper folding of the inactive zymogen so the functional enzyme can be released once 
the EK peptide is proteolytically removed. Because EK also activated EK-PSA-TRP and 
EK-PSA-GZMB robustly, it also strongly suggests that the DDDDK peptide also plays a 
major role in inhibiting the enzymes and retaining the inactive conformation, possibly due 
to the very strong ionic charge and secondary structure formed by the piece. It is 
interesting that the PSA-TRP protein retained some activity once activated by PSA as 
opposed to the PSA-GZMB protein suggesting the TRP is more tolerant about which 
peptides reside on its N-terminus for proper expression and folding. Because the 
DDDDK EK piece seems to promote folding, proper presentation of the KGISSQY 
peptide activation substrate, and direct inhibition of the enzymes when attached, we 
highly recommend it’s use as a pro-piece for any further mutant serine proteases that 
require activation by a target protease.  
In order fully characterize both EK-PSA-GZMB and EK-PSA-TRP’s ability to target cells 
in culture. We assessed this by incubating both drugs in serum free media (to facilitate 
88 
 
PSA activation) on cells plated on a bed of matrix proteins derived from FBS. On LNCaP 
prostate cancer cells, we observed obvious morphological and proliferative effects from 
both drugs only when PSA and the pro-drug were co-incubated. While EK-PSA-GZMB 
had these effects on various other prostate cancer cell lines to a varying degree, we did 
not observe these effects on any other cell line when using EK-PSA-TRP including 
DU145. This may be  due to the fact that many cancer lines secrete anti-trypsin protease 
inhibitors as a mechanism to prevent extracellular damage via trypsin and trypsin like 
proteases. GZMB, on the other hand, has been shown to be inherently resistant to 
inhibition via serum protease inhibitors which would explain the discrepancy between 
these two drugs (13). Regardless, we were pleased to see our GZMB pro-drug to have 
these effects on several lines in the presence of PSA as well as human prostate stromal 
cells which suggests that GZMB could have the capacity to disrupt the tissue 
architecture in a tumor which would yield a more comprehensive response. It is also 
worth noting that some cell lines (PC3 and LAPC4) were affected morphologically but 
not in terms of growth suggesting that these ECM interactions and their role in cell 
biology differs wildly between tumors. 
 To ensure whether GZMB’s effects were solely due to ECM damage, we treated plates 
coated with ECM proteins from FBS with GZMB in a cell free context and then plated 
cells in serum free media once the GZMB was removed. We observed very similar 
effects on both cell lines which were sensitive to GZMB in co-culture experiments. 
Because GZMB was removed from the plate once the cells were added and that the cell 
morphology was very similar to that of the cells incubated on an empty plate with no 
ECM, it is reasonable to conclude that a majority the effects seen were due to ECM 
damage caused by GZMB proteolysis. It is possible; however, that the anti-proliferative 
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effects seen on the cells were due to factors other than ECM damage, as it appears the 
cells grew slightly better than when incubated with GZMB directly.     
Despite observing robust in vitro effects of these PSA-activated proteases, we observed 
no obvious antitumor effects of the drugs when injected IV or IT into LNCaP-bearing 
nude mice at any dose. While disappointing, this lack of efficacy may be due to not 
enough enzymatically active PSA being expressed by the tumors themselves as LNCaP 
xenografts, though PSA positive, do not produce near the levels of enzymatic PSA as 
human tumors. Because we used physiologically relevant concentrations of active PSA 
in our tissue culture experiments, we would expect these pro-drugs to be functional in 
the context of the prostate cancer microenvironment in a human. It is also possible that 
these drugs may not be able to generate anti-tumor effects by themselves and may need 
other means of chemotherapy to synergize with. While speculative, it is evident based 
on the observed in vitro effects that prostate cancer cells under duress will aggregate 
together in order to avoid undergoing anoikis or other negative effects. It is possible that 
combing our GZMB pro-drug with an agent that blocks these interactions, such as an E-
cadherin antibody, may facilitate a synergistic anti-tumor effect. Given that GZMB 
extracellular effects seems to be pro-inflammatory, it is possible  that a GZMB pro drug 
could be used to recruit local immune cells to the tumor and help facilitate an anti-tumor 
immune response. Our GZMB pro drug may be best used with immune check point 
inhibitors or other types of clinically approved cancer immunotherapy.  
We successfully engineered two human enzymes to be activated by cancer-specific 
proteases not active in the bloodstream. These pro-drugs had favorable enzymatic 
activity characteristics while having some interesting anti-cancer activity in vitro. We are 
encouraged by this work as it elucidates a novel mechanism to regulate and engineer 
human proteases, one of the largest and most diverse classes of enzyme, to be 
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activated by other proteases of interest. We postulate that the use of the EK inhibitory 
peptide and a known protease site could be used to modulate the activity of a number of 
proteases via proteolytic activation of a number of other target proteases. We are also 
encouraged by the idea of using therapeutic agents to generate a field effect that 
prevents tumor cells from thriving. Virtually all currently approved therapeutics directly, in 
one way or another, interact with the cancer cells. We have demonstrated a strategy to 
selectively modify a microenvironment so that it changes tumor biology and generate an 
anti-tumor response. Should similar means be used successfully in in vivo models, these 
therapies may have the capacity to minimize recurrence of resistant cancer cells and 
combat the problem of tumor heterogeneity which has limited the efficacy of therapeutic 
strategies in extending and improving the quality of lives in patients.  
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Chapter 4: Targeted Delivery of Cytotoxic Proteins via Small Molecule Peptidase 
Inhibitors 
Abstract 
Prostate cancer is the leading cause of cancer death in American men. This is despite 
countless advancements in understanding the biochemical and physiological properties 
that drives lethal disease. Currently, there are no approved curative therapies for 
metastatic prostate cancer. Protein-based targeted agents offer a unique advantage to 
treating metastatic tumors due to their natural tendency to accumulate in the tumor 
micro-environment. In order to further improve selectivity and minimize systemic toxicity 
of such an agent, our lab has previously explored and evaluated novel ways to regulate 
cytotoxic proteins for therapeutic purposes. Prostate Specific Membrane Antigen 
(PSMA) is an extracellular carboxy-peptidase-like enzyme expressed in both benign and 
cancerous prostate epithelium. PSMA has been classically shown to be aggressively 
upregulated by metastatic prostate cancer cells and is a reliable predictor of recurrent 
and more aggressive disease. Recently, a small class of urea-linked dipeptide inhibitors 
has been developed against PSMA in order to selectively deliver imaging agents to 
tumor cells. We hypothesize that conjugation of protein cytotoxins with these PSMA-
binding ureas would yield a novel and potent agent capable of selectively binding PSMA 
and entering the tumor cell and induce subsequent cell death. To evaluate this, we 
synthesized two protein-urea cytotoxins using the apoptosis-inducing protease 
Granzyme B and the potent bacterial protein toxin fragment, PE35. In this study, we 
demonstrate the synthesis and biochemical properties of these agents and compare 
their ability to target PSMA-expressing cells in culture. Furthermore, we also 
characterize the anti-tumor effects of the PE35-urea conjugate in xenograft-based 
animal models. This study demonstrates the properties of these molecules and 
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correlates these properties with their efficacy as well as describes effective methods to 




Every year, hundreds of thousands of American men are diagnosed with prostate cancer 
(1). Fortunately, a majority of these men go on to survive years after their initial 
diagnosis. Despite the disease’s high survival rate relative to other solid malignancies, a 
subset of patients will succumb to their cancer. Most of these patients, at time of 
diagnosis, presented with metastatic prostate cancer (MPC) as opposed to disease 
localized in the prostate. It is clear that the focus in treating prostate cancer should be on 
metastatic, therapy resistant tumors that ultimately contribute to the mortality of this 
disease. Currently, there is no approved cure for metastatic prostate cancer. While 
therapeutic options have expanded in recent years, these treatments usually expand life 
marginally and are usually palliative. One major challenge associated with treating MPC 
is that these tumor cells grow much more slowly than other cancers. While this likely 
plays a role in the longevity associated with prostate cancer, it renders most tumors 
insensitive to traditional chemotherapeutic approaches. It is, therefore, essential that 
novel chemical approaches to targeting these tumors work independently of cell 
proliferation, as most cells within a patient are in the G0 stage of the cell cycle at any 
given point. Because of this, our lab has become intrigued by the idea of re-targeting 
highly potent and robust environmental toxins to MPC cells via biochemical engineering 
techniques.  
Of all the potential markers selective to MPC cells, few are as enticing as the Prostate 
Specific Membrane Antigen (PSMA). PSMA is a membrane-bound extracellular 
carboxypeptidase enzyme expressed by prostate epithelial cells (2). Its function in both 
normal and malignant biology has not been fully characterized despite the discovery of a 
panel of specific of diverse substrates. One such substrate is the neurotransmitter N-
acetyl-aspartyl-glutamate (NAAG). PSMA processes this dipeptide into N-acetyl-
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aspartate and free glutamate (3). In the context of prostate cancer, PSMA has been 
shown to be over-expressed in neoplastic tissue as it transitions from normal to 
malignant and has increased activity in prostate cancer cells compared to normal (4,5). It 
has also been proposed in the literature that PSMA is an accurate predictive marker of 
recurrent, more aggressive prostate cancer as tumors over-expressing the gene were 
more likely to suffer future relapse and relapsed faster than patients who did not at time 
of diagnosis (4). Because of PSMA’s strong association with aggressive, more resistant 
prostate cancer, it’s unique extracellular catalytic activity, it’s expression in neo-
vasculature in non-prostate cancer tumors (6) and its rapid recycling in cells (7), it is an 
excellent choice as a target for delivering cytotoxic payloads to MPC cells, as a number 
of PSMA-targeted antibodies have been in development for the treatment and diagnosis 
of prostate cancer (8) 
Recently, a class of urea-linked dipeptides was developed as imaging agents for MPC. 
These agents (deemed ‘ureas’ or PSMA-binding ‘ureas’ in this work) contain a glutamate 
and lysine residue linked by a urea group rather than an amide (9). PSMA-ureas bind 
remarkably well to the catalytic pocket of PSMA and inhibit its enzymatic activity. It has 
also been shown that these compounds are capable of delivering low molecular weight 
cargo to PSMA-expressing cells with remarkable selectivity given the simple molecular 
structure of the urea backbone. One such molecule was developed by Chen et al in 
which the infrared-fluorescent dye IR800CW was covalently coupled to the PSMA-
binding urea scaffold. This compound selectively concentrated into a PSMA-expressing 
PC3 xenograft and was barely detectable in a PSMA-null control xenograft in IR-based 
imaging experiments demonstrating the impressive ability to selectively deliver cargo 
molecules to PSMA-producing tumors (10). Because of this, we hypothesize that PSMA-
binding ureas can serve as effective and specific ‘Trojan horse’ molecules to facilitate 
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the delivery of cytotoxic protein payloads which have been shown to naturally 
accumulate into tumors via the Enhanced Permeability and Retention effect (11).  
In order to evaluate the potential of developing a ligand-targeted cytotoxic protein 
conjugate via a PSMA-binding urea, we chose to conjugate two diverse yet well 
understood proteins capable of inducing rapid and comprehensive cell death and 
compare their biochemical and pharmacological properties. The first protein we selected, 
human Granzyme B (GZMB), is a caspase-like serine protease secreted by activated 
cytotoxic T lymphocytes upon stimulation by a neoplastic or virally infected cell (12). 
GZMB, when co-secreted with the pore-forming protein perforin, is translocated into the 
target cell cytoplasm where it is able to cleave a myriad of pro-apoptotic and anti-survival 
substrates thus inducing cell death (13). While GZMB is a well-studied and effective 
killer of mammalian cells, its function is dependent on perforin facilitated endocytosis 
and translocation from the target cell endosome to the cytoplasm (14,15). Because 
PSMA-ureas concentrate in the perinuclear endosome space due to PSMA”s recycling 
pathway, we postulated that GZMB-urea conjugates may not induce cell death at 
relevant concentrations. We also selected a cysteine-containing fragment of the 
pseudomonas exotoxin A gene (PE35), a bacterial toxin enzyme which disrupts target 
cell translation via ADP-ribosylation of the crucial diphthamide residue on Elongation 
Factor 2 (16). PE35 is an engineered cytotoxin whose ability to bind and internalize into 
cells has been perturbed via deletion of the cell targeting domain Ia structure (17). 
Currently, there are several immunotoxins containing PE fragments in the clinical setting 
(18), with one, moxetumumab, in Phase III studies for the treatment of Hairy Cell 
Leukemia (19).  Because PE35 has been shown to be able to escape cell endosomes 
upon delivery via antibodies or growth factors, we rationalized that PE35 would still be 
functional despite endosome localization via PSMA’s recycling pathway.  
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In this study we design, synthesize, and evaluate two protein-urea conjugates using the 
GZMB and PE35 proteins as cargo. To accomplish this, briefly, we used mutants of 
these proteins that contain reactive cysteine residues capable of reacting with maleimide 
moieties. PSMA-binding urea compounds were synthesized with a reactive maleimide 
functional group linked by 2 PEG units (compound referred to as MU2). Once 
synthesized and purified, these conjugates were evaluated for their ability to bind and 
inhibit PSMA, internalize into PSMA-expressing cells, and their ability to target MPC cell 
lines in vitro and in vivo in a PSMA-specific manner.  
Materials and Methods 
Materials  
For synthesis of the MU2 compound, Preparative reverse phase chromatography was 
performed on a Biotage Isolera One Purification system using a SiliCycle 25g C18 
column (SiliCycle Inc., Quebec, Canada) (230-400 mesh, 40-63 micron column) and a 
gradient elution of 95% solvent A, 5% solvent B to 60% solvent A, 40% solvent B over 
20 minutes where solvent A is 100% water + 0.1% TFA and solvent B is 100% 
acetonitrile + 0.1% TFA and flow rate is 25mL/min. HPLC analysis was performed on an 
Agilent 1260 Infinity HPLC system (Santa Clara, CA, USA) using a 10 X 250 mm Luna 
C18, 10 micron column (Phenomenex, Torrance CA, USA) and a gradient elution of 90% 
solvent A, 10% solvent B to 10% solvent A, 90% solvent B over 30 minutes where 
solvent A is 100% water + 0.1% TFA and solvent B is 100% acetonitrile + 0.1% TFA at a 
flow rate of 5mL/m. 1H-NMR spectra was measured on a Bruker Avance 400 MHz 
spectrometer. Mal-PEG2-NHS was purchased from BroadPharm (San Diego, CA, USA). 
For protein and biological studies, all reagents were purchased from Sigma Aldrich 
unless stated otherwise.  
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Synthesis of maleimide-linked PSMA-binding ureas for conjugation 
(3S,7S)-22-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,13,20-trioxo-16-oxa-4,6,12,19-
tetraazadocosane-1,3,7-tricarboxylic acid, 3. 
To a solution of the Lys-Glu urea amine formate salt (20) (100 mg, 0.19 mmol) and 
DIPEA (131 µL, 0.75 mmol) in anhydrous DMF (1.5 mL), was added Mal-PEG2-NHS 
(104 mg, 0.24 mmol) in one portion and allowed to stir at ambient temperature.  After 1 
h, DMF was evaporated off and crude 2 was dissolved in 1.5 mL of TFA/methylene 
chloride (2:1) and allowed to stir overnight.  The solvent was then concentrated under 
reduced pressure, and the crude mixture purified by reversed phase chromatography 
using a C18 column and eluting with a gradient of 95:5 water (0.1% TFA)/acetonitrile 
(0.1% TFA) to 60:40 water (0.1% TFA)/acetonitrile (0.1% TFA) over 20 mins.  After 
lyophilization, the product was obtained as a white flaky solid.  The isolated yield is 75 
mg (64%).  Purity as measured by HPLC was 95%. 1H-NMR (400MHz, DMSO-d6): 8.01 
(br, 1H), 7.80 (br, 1H), 6.99 (s, 2H), 6.29 (br, 2H), 4.16−3.93 (comp, 2H), 3.67−3.51 
(comp, 5H), 3.50−3.40 (comp, 5H), 3.38−3.27 (comp, 2H), 3.19−3.07 (comp, 2H), 
3.05−2.94 (m, 1H), 2.46−2.38 (m, 1H), 2.37−2.15 (comp, 5H), 1.98−1.82 (m, 1H), 
1.78−1.56 (comp, 2H), 1.55−1.43 (m, 1H), 1.43−1.17 (comp, 3H);  MS: calculated for 
[C26H40N5O13]+, 630.6 [M + H]+; found 630.4. 
Cloning of GZMB gene and cysteine 248 mutagenesis 
We chose to design a GZMB expression construct as was done by Gehrmann et al (21). 
Briefly, GZMB was cloned with two modifications for rapid and efficient expression and 
urea conjugation. First, we removed the native two amino acids on the N-terminus of 
GZMB and replaced them with an enterokinase substrate, DDDDK. This was shown to 
improve expression yields and minimize toxicity on HEK-293T cells. Second, we inserted 
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a C-terminal reactive cysteine due  to previous works in which GZMB immunotoxins 
were synthesized with the targeting moiety on the C-terminus. To clone the gene into a 
mammalian expression vector, we amplified the GZMB gene (Origene plasmid 
SC3231693) with the primers F: CAGTGTGGTGGAATTCATGCAACCAATCCTGCTTC 
R: GATATCTGCAGAATTCTTAGTAGCGTTTCATGGTTTT using an Accuprime Pfx 
PCR mix (Thermo  12344024) according to manufacturer’s instructions with a melting 
temperature of 53 degrees Celsius. PCR product containing the GZMB gene with a C-
terminal cysteine (C248) was then purified on a 1.5% agarose gel and cloned into the 
mammalian expression vector pcDNA3.1 using an In-Fusion HD cloning kit (Clonetech 
638909) according to manufacturer’s instructions. Plasmid was then grown up and 
isolated using Stellar Competent E Coli (CloneTech 636763) according to 
manufacturer’s instructions. The correct product was harvested and isolated using a 
PureLink® HiPure Plasmid Filter Maxiprep Kit (Thermo K210017) out of 50 mL of cell 
suspension and sequenced using the Sanger method via the Johns Hopkins Sequencing 
and Synthesis core facility.  
The DDDDK EK piece was inserted using a Q5 Site Directed Mutagenesis Kit (E0554S) 
and the primer set F:  CGACAAAATCATCGGGGGACATGAGG  R: 
TCGTCGTCTGCATCTGCCCTGGGCAG using a melting temperature of 67 degrees 
Celsius. Product was transformed, grown, harvested, and sequenced as described 
above. For all work with pcDNA3.1-transformed E Coli, a solution of 100 ug/mL 
Ampicillin was used in LB. All cells were plated on 1.5% agar plates containing 100 
ug/mL Ampicillin.  
Expression  and harvesting of GZMB and PE35 proteins 
Based on the work done by Gehrmann et al, we expressed EK-C248 GZMB in HEK-
293T cells. HEK cells were grown in T75 flasks in 20 mL DMEM containing 10% FBS 
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and supplemental L-glutamine (5mM) at a seeding density of 5 x 106 cells per flask. 
Twenty four hours following seeding, cells were transiently transfected with 25 ug of 
plasmid mixed with 1.1 mL of OPTI-MEM media and 74 uL of FuGene HD lipofectamine 
reagent (Promega E2311) per T75 which was incubated for 10 minutes at room 
temperature. The mix was then added to cell culture and incubated overnight at 37 
degrees. The next day, cells were washed one time with 1X PBS solution and cultured in 
10 mL serum-free DMEM containing glutamine and incubated for 3 days or longer. To 
harvest, cell supernatant was collected and centrifuged for 10 minutes at 8000 x g in 
order to remove insoluble debris. The solution was then concentrated to less than a mL 
using Amicon Ultra-15 Centrifugal Filter Units (Millipore UFC901024) and stored until 
needed at 4 degrees.  
The plasmid containing PE35 with a reactive cysteine near the N-terminus of the protein 
pCT11 (21) was generously donated to us by the laboratory of Dr. Ira Pastan. This 
plasmid was transformed into BL21 DE3 E Coli according to manufacturer’s instructions 
and grown on plates containing 50 ug/mL Ampicillin. Colonies were picked and grown up 
in 500 mL TB containing Amp until the optical density reached 0.4. The culture was then 
induced using 500 uM IPTG and incubated overnight at room temperature, shaking at 
250 RPM. The next day, the culture was pelleted via a 5000 x g spin for 20 minutes and 
the periplasmic fractions were harvested. To do this, the pellet was then resuspended in 
a solution of 15 mL 30 mM Tris pH =8, with 150 mM NaCl, 20% sucrose, 0.5 mM EDTA 
and  cOmplete protease inhibitor cocktail in order to osmotically shock the cells. Cells 
were incubated for 15 minutes on ice and re-pelleted using a 5000 x g spin for 20 
minutes. Supernatant was saved and shock protocol was repeated using reverse 
osmosis water. The supernatant was combined with the first fraction and spun at 10,000 
x g for 10 minutes to remove any insoluble debris. The resulting supernatant was then 
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concentrated using Amicon filters to less than a mL and then diluted in 20 mL of PBS 
with a pH = of 6.5. To clean up this solution, we then added 1 mL of washed Q 
Sepharose Fast Flow anion exchange resin (GE Healthcare 17-0510-10) and incubated 
for 20 minutes at room temperature. The beads were loaded into a disposable column 
and washed twice with 10 mL of PBS. PE35 was then eluted from the column using 4 
fractions of 0.5 mL PBS pH = 6.5 containing 1 M NaCl. Fractions were then pooled and 
dialyzed vs 1 L PBS pH = 7.4 in a Slide-a-Lyzer Dialysis Cassette (MWCO 7K) (87722) 
for 2 hours at 4 degrees and then overnight vs 2 L of buffer in order to remove the 
excess salt. Dialysate was then stored at 4 degrees until needed. Protein concentrations 
were determined by A280. Content of each prep was validated with reducing SDS 
PAGE.  
Protein-MU2 conjugations and chromatography 
In order to maximize the efficiency of protein-urea coupling, proteins were gently 
reduced prior to coupling. Because contaminating thiol groups can compete with the 
protein cysteine thiols, we used the non-sulfur containing reducing agent TCEP to 
disrupt inter-protein disulfide dimer formation. This was done by incubating TCEP in 
water and diluting to a concentration of 0.5 mM (at least 5-fold excess of protein) at room 
temperature for at least an hour. We then diluted 1-2 mg of MU2 (compound 3) in water 
and adjusted the pH of this solution to 6-7 as the initial solution has a pH of 
approximately 2 and cysteine-maleimide coupling reactions are very pH sensitive. The 
solution of MU2 was diluted to 1 mM in the reduced protein solution and incubated at 
room temperature for an hour and then at four degrees overnight. For BSA conjugation, 
because Ellman’s assay was used to characterize the coupling, no reducing agent was 
added, as it reacts rapidly with Ellman’s reagent.  
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Prior to conjugation, GZMB-MU2 was activated using EK to release the fully functional 
enzyme. Purified EK from porcine intestine was diluted in a solution of 10 mM TrisHCl 
and 10 mM CaCl2 and diluted to a solution of 5 EU/mL and digested for 30 minutes at 37 
degrees. To purify the GZMB-MU2 conjugate (and remove the excess MU2 and EK), we 
performed cation exchange chromatography using a negatively-charged SO3- resin 
(Fractogel EMD SO3- Millipore 116882). Coupling reaction and 1 mL washed resin was 
diluted in 10mL PBS pH= 7.4 and incubated at room temperature for 20 minutes 
shaking. This solution was then loaded into a disposable column and washed with 20 mL 
of PBS. Protein was then eluted using PBS containing 1M NaCl in 0.3mL fractions. 
Protein containing fractions were dialyzed as described above to remove the excess 
salt.  
For PE35-MU2, we used gel filtration chromatography on a Fast Protein Liquid 
Chromatography apparatus. Briefly, the conjugation reaction was spun at 18,000 x g for 
10 minutes and loaded into an AKTAprime Plus FPLC System (GE 11001313) using a 
washed HiLoad Superdex 200 PG (GE 28989335) column. One milliliter fractions were 
collected and monitored using A280 spec. Fractions containing protein were then run on 
SDS PAGE. All fractions containing primarily the band specific for PE35 were pooled 
and concentrated to less than 1 mL. This method was also used to purify Fluorescein-
labeled PE35-MU2.  
Fluorescein Conjugation of protein-ureas  
To create fluorescent probes whose uptake can be monitored using a confocal 
microscopy-based assay, we synthesized fluorescein-labeled protein-MU2 constructs. 
This was done by using NHS-fluorescein (Thermo 46410). Free amines on each protein 
were labeled by incubating NHS-Fluorescein (dissolved in DMSO) with the crude 
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reaction (prior to purification) for one to two hours at room temperature in the dark. Free 
NHS-Fluorescein was removed using either Pierce™ Dye Removal Columns (Thermo 
22858) according to manufacturer’s recommendations or via FPLC. Conjugation 
efficiency was determined using the ratio between A280 and A495 using the respective 
molar extinction coefficient for each protein, and the fluorescein conjugate.  
Validation of Protein-urea Conjugation 
To assess whether or not each protein-drug conjugate was synthesized successfully, we 
used either the thiol-reactive chromogenic reagent DNTB (Ellman’s reagent), the 
fluorescent substrate ABDF, or a non-reducing SDS PAGE gel based assay. For the 
DNTB assay, thiol concentrations must be above 50 uM. BSA solutions plus or minus 
MU2 were mixed 1:1 with a 2mM solution of DNTB in DMSO. The reaction was then 
incubated at room temperature for 10 minutes shaking and read at 412 nm. 
Concentration of thiol was determined using the molar extinction coefficient of DNTB. 
For the gel-based assay, GZMB solutions plus or minus conjugate were purified and 
dialyzed as described above which allowed any free thiol to form disulfides. The 
reactions were then run on a non-reducing SDS PAGE gel using a BioRad Mini-Protean 
gelcast system (BioRad 1658005) with Mini-Protean 4-15% pre-cast gels. Gels were run 
at 150V for 45 minutes, washed once with water, stained with  SimplyBlue (Thermo 
LC6060) protein stain, and de-stained in water.  The ABDF assay was performed using 
a Sensolyte ABDF Assay Kit (Anaspec AS-72137) according to manufacturer’s 
recommendations. The plate was read at 389/513 ex/em.   Free thiol concentrations of 
PE35 plus or minus MU2 were determined using a GSH standard curve.  
PSMA enzymatic assay 
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To confirm successful protein-drug coupling and that the MU2 compound is capable of 
binding PSMA, we performed an enzymatic assay specific for PSMA activity and 
correlated inhibition of substrate hydrolysis with protein-urea binding. Lysate from 
LNCaP cells (robustly PSMA positive) was generated by pelleting cells from culture, 
lysing them in a solution of 50 mM Tris HCl pH=7.5, 140 mM NaCl, and 1 % Triton X-100 
to a concentration of 1 x 107 per mL of solution. Cells were then incubated on ice for 15 
minutes and then spun at 18,000 x g for 15 minutes. Supernatant was then harvested 
and stored at -80 degrees Celsius or used immediately. The lysate was then diluted 1:10 
in PBS and incubated with the PSMA specific substrate N-acetyl-aspartyl-glutamate 
(diluted to a final concentration of 4 uM) (NAAG) and either buffer, a protein-urea 
conjugate solution, a naked protein solution, or a control urea molecule, ZJ43 to validate 
the assay. This mix was incubated at 37 degrees Celsius for 4 hours. To determine the 
amount of NAAG converted to N-acetyl-aspartate and free glutamate by PSMA in each 
sample, we then added a fluorescent enzyme-coupled Amplex Red Glutamic 
Acid/Glutamate Oxidase Assay Kit (Thermo A-12221) mix according to the protocol 
provided. This reaction was done in Costar™ 96-Well Half-Area Plates (Fischer Corning 
3694) in 100 uL total volume and was incubated for one hour at 37 degrees Celsius in 
the dark. The plate was then read at 530/590 nm ex/em. Activity was measured in raw 
RFUs and inhibition curves were based off a variable 4 parameter nonlinear regression. 
Naked and conjugated protein activity was measured in terms of % untreated controls.  
GZMB Functional Assay 
Once GZMB and MU2 had been successfully conjugated, we aimed to ensure that the 
MU2 coupling had no effect on the actual function of the enzyme. To evaluate GZMB 
activity, we used a GZMB-specific enzymatic assay (Biovision K168-100) that measures 
the cleavage of the peptide IETD and release of the fluorophore amino-methyl-coumarin 
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(AMC). Assay conditions were run according to manufacturer’s suggestions. The plate 
was read at 380/500 ex/em following incubation. This reaction with GZMB or GZMB-
MU2 was compared to a standard curve of free AMC to calculate the amount of 
substrate released. 
In Vitro Characterization of Protein-Urea Conjugates 
All cell lines were grown in RPMI containing 10% FBS with supplemental L-glutamine at 
5mM and were passaged weekly. All experiments using PIP and Flu-PC3 cells were 
performed in the presence of 2 ug/mL puromycin in order to maintain PSMA/control 
plasmid expression respectively. At day -1, all cells were passaged and plated at the 
following densities based on their growth. PIP/Flu-PC3 were plated at 500 cells per well, 
DU145 at 1000 cells per well, CWR22 Rv1 at 2000 cells per well, and LNCaP/LAPC4 
(grown in IMDM with serum and glutamine) at 5000 cells per well. Twenty four hours 
later, cells were treated with either vehicle (PBS pH=7.4) or the protein drug conjugate of 
interest at doses up to 250 nM. For GZMB-MU2, doses of 100 nM were not exceeded 
due to GZMB’s ability to affect cell growth via extracellular matrix remodeling. All drug 
dilutions were made at 2x and diluted 1:1 in media to their final concentration in the dish. 
On day 5, 100 uL of media was removed from each well and 15uL of MTT dye (Promega 
G3582) was added. Plates were incubated at 37 degrees for 4 hours and stopped using 
the provided Stop solution. The assay was then incubated at room temperature shaking 
for up to 24 hours and read vs wells containing no cells at A570-A650. A standard curve 
was then used to calculate the number of cells in each well. Figures represented as a 
percentage of vehicle-treated cells. To assess the potency of each drug, we used a non-
linear, 4 parameter, normalized inhibition curve to determine the IC50.  For the pulse-
soak PE35 experiments, we incubated cells for 24 hours with the drug, removed the 
media, and supplemented the cells with fresh media and compared the efficacy to cells 
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soaked in the drug for 5 days. Cells were photographed using a Nikon TE200 
fluorescence microscope with the Metamorph software package at indicated 
magnifications.  
Flor-Protein-Urea Confocal Uptake Assay 
To assess the ability for PSMA-producing cells to internalize Fluorescein-labeled GZMB-
MU2 or PE35-MU2, we treated PIP-PC3 and Flu-PC3 cells with both conjugates and 
used fluorescein uptake as a read out when visualized via confocal microscopy. This 
assay also allowed us to visualize where the constructs were being compartmentalized. 
We plated PIP and Flu cells at confluency on 12-well glass microscope plates (MatTek 
P12G-1.5-10-F) and incubated overnight. The next morning, cells were treated with 100 
nM of the protein-drug conjugate for 2 hours at 37 degrees Celsius. We also added 10 
uM 2-PMPA, another competitive inhibitor of PSMA to assess the specificity of the 
uptake for PSMA. The media was then removed and cells were washed three times with 
PBS. The cells were then incubated with 0.5 mL of Methanol for 30 seconds in order to 
fix and permeabilize them. Next, we added ProLong DAPI-containing mountant (Thermo 
P36962) and allowed the plates to dry for 10 minutes at room temperate in the dark. To 
visualize the cells we used a Nikon C1si True Spectral Imaging Confocal Laser 
Scanning Microscope System. All images were analyzed using ImageJ software. All 
images are at 20X magnification unless stated otherwise.  
In vivo characterization of PE35-MU2 
We grew LNCaP cells (passage 30), PIP, and Flu cells in culture in order to inoculate 
mice for xenograft studies. Cells were cultured, trypsinized, and resuspended in a 90% 
matrigel suspension for inoculation. Either one million PIP/Flu cells or 2 million LNCaP 
cells were injected subcutaneously into nude male mice. Animals were then monitored 
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until tumors reached at least 0.1 (PIP/Flu) or 0.3 (LNCaP) cubic centimeters in volume. 
We then injected 20 ug of PE35-MU2 or naked PE35 intratumorly consecutively for two 
days and then measured tumor volume and animal weight every three days. For IV 
efficacy studies, animals were dosed with 50 ug (2 mg per kg) drug via tail vain injection. 
Once tumors grew larger than 1 cc, animals were sacrificed via CO2 asphyxiation. 
Tumors were then excised, weighed, and fixed in formalin solutions. Tumor histology 
was then performed by the Johns Hopkins Histology core facility. For the LNCaP 
models, we also determined circulating PSA via ELISA by collecting blood retro-orbitally 
and submitting the sample to the Johns Hopkins clinical chemistry core facility.  
Results 
 
Using the PSMA-binding scaffold, we opted to synthesize a readily conjugatable, thiol 
reactive species linked together by 2 PEG units. This was done by reacting the scaffold’s 
free amine (from the lysine side chain) with a maleimide-containing a linker with a 
reactive N-Hydroxysuccinimidyl ester (Figure 1A). These two were linked by 2 
polyethylene glycol subunits and yielded a maleimide linked, PSMA-binding urea 
deemed MU2. Mass spectrometry of the compound showed a single major peak with a 
m/z value of 629, the expected molecular weight of MU2. The lack of other peaks 
suggests the compound is relatively pure (Figure 1B). Using simple amino acid 
mutagenesis, we designed two protein-drug conjugates by introducing cysteine residues 
capable of covalently reacting with the maleimide group on MU2. This reaction can be 
robustly done at pH 7-8 in aqueous buffered solutions favoring the protein’s stability and 




Once the MU2 compound was validated and cysteine-containing mutants were 
generated of GZMB and PE35, we performed covalent couplings in the presence of the 
thiol-free reducing agent TCEP. Because Bovine Serum Albumin already contains a 
readily reactive, external cysteine, we opted to assess the ease and feasibility of MU2-
protein coupling. Ellman’s assay analysis showed that approximately 40% of cysteine 34 
in BSA is reactive at pH 7.4 in aqueous solution under non-reducing conditions. Once 
MU2 was mixed with the protein overnight, we detected zero free thiols in solution 
(Figure 1D). To confirm successful coupling with EK-activated C248 GZMB, we ran both 
naked and coupled protein through ion exchanged, dialyzed overnight, and ran on a 
Figure 1: Synthesis and production of protein-urea drug conjugates. 
Chemical synthesis scheme taken to make a thiol-reactive maleimide-linked 
urea separated by two PEG units (MU2) (A). Mass spectrometry plot of 
MU2 product (B). Diagram depicting the protein-MU2 conjugation  reaction 
(C).  Ellman’s reagent assay of BSA +/- MU2 under non-reducing conditions 
(D). Non-reducing SDS PAGE gel of C-terminal reactive GZMB +/- MU2 
following dialysis (E). ABD-F fluorescent assay of PE35 +/- MU2 (F).   
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non-reducing SDS PAGE gel. Once stained, gel analysis showed that dialyzed C248 
exists in both dimeric and monomeric states with the majority of the material being linked 
via disulfides. GZMB mixed with MU2, conversely, existed in primarily the monomeric 
state at the expected molecular weight of 28 kDa (Figure 1E). Lastly, we used the thiol-
reactive, fluorescent ABD-F assay to confirm coupling between MU2 and a mutant of PE 
containing a cysteine, PE35.  This assay showed that uncoupled PE35, under reducing 
conditions, a 0.5 mg/mL solution of protein (14 uM) had a free sulfhydryl content of 10 
uM while the couple material had a free sulfhydryl content of 4 uM (Figure 1F).  
 
Figure 2: Protein-urea conjugates bind and inhibit PSMA. Scheme of the 
enzyme-coupled PSMA enzymatic assay utilized to detect urea-conjugate 
binding (A). Inhibition of PSMA by coupled or naked cytotoxic proteins 
represented as a percentage of the control reaction (B). Dose response 
curves of ZJ43 (top left), BSA-MU2 (top right), GZMB-MU2 (bottom left), and 
PE35-MU2 (bottom right) (C). Table describing the IC50 values for PSMA 
obtained for each compound (D).     
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Because PSMA is both expensive and difficult to express at reasonable quantities, we 
opted to use a cell lysate-based coupled enzyme assay to measure our protein-drug 
conjugates’ ability to bind to the protein. Briefly, PSMA from LNCaP cell lysate, cleaves 
the substrate NAAG to NAA and free glutamate. We then added a reaction mix that 
converts glutamate to alpha-ketoglutarate via glutamate oxidase generating hydrogen 
peroxide in aqueous solution. Horseradish peroxidase can then catalyze the conversion 
of a non-fluorescent probe to a fluorescent species easily detected at 530/590 
excitation/emission (Figure 2B). When compared to buffer-treated controls, both GZMB 
and PE35 proteins have no effect on this assay. However, conjugated GZMB and PE35 
proteins both inhibited PSMA enzymolysis at 1 uM (Figure 2B). For all three protein-urea 
conjugates (including BSA), we observe a dose dependent, 4 parameter inhibition of 
PSMA in this assay with increasing inhibition upon increasing conjugate concentrations 
(Figure 2C). We observe IC50 values within the same range for all three protein 
conjugates while the control urea compound, ZJ43, has an IC50 of 1.9 nM, consistent 
with that published by Zhou et al (Figure 2D).  
PSMA-binding assays confirmed that the urea portion of the conjugate was still 
functional following conjugation, however, it was unclear whether protein functionality 
was affected by this modification. We assessed this using a Granzyme B specific 
proteolysis assay with both naked and coupled expressed GZMB. We observe no 
change in specific activity per mg protein between naked and conjugated GZMB (Figure 
3A). When tested at doses up to 300 nM, we observed no effect on proliferation, cell 
morphology, or viability on any cell lines regardless if  PSMA was expressed or not 
(Figure 3B). For LNCaP cells, we do observe toxicity at doses above 300 nM that affects 
morphology and cell proliferation but this was not enhanced when the urea moiety was 
present (data not shown). To assess whether or not the lack of toxicity was due to lack 
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of internalization or whether GZMB was not functional in this intracellular context, 
fluorescein-tagged GZMB-MU2 was dosed on cells at 100 nM for two hours. We also 
stained these cells with DAPI in order to contextualize any observed uptake. After a 1 
hour incubation, we observe positive staining on the PIP-PC3 cells in the fluorescein 
channel but not on the Flu-PC3 cells. The staining on the PIP-PC3 cells appears most 
punctate and associated with the DAPI stain with some association to the membrane 
(Figure 3C). When the magnification of the PIP cells is increased to 60x, we observe 
Figure 3: GZMB-MU2 internalizes into PIP cells but does not induce cell 
death. Enzymatic activity of GZMB or GZMB-MU2 using a GZMB-specific 
fluorescent substrate (A). Cytotoxicity of purified GZMB-MU2 on PIP-PC3 (top 
left), Flu-PC3 (top right), LAPC4 (bottom left), or CWR22 Rv1 (bottom right) 
(B). Confocal microscopy of PIP or Flu-PC3 cells treated with Flor-GZMB-
MU2 for 1 hour at 20X magnification (left) or 60X (right) (C).  
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compartmentalization of the signal both a large foci near the nuclear space of the cell 
and in smaller foci distributed throughout the cytoplasm of the cell.  
 
To determine the ability of PE35-MU2 to kill cells in a PSMA specific manner, we first 
treated PIP and Flu-PC3 with both conjugated and naked PE35. Somewhat surprisingly, 
we observed a cytotoxic effect of the unconjugated material on both PIP and Flu-PC3 
cells with little difference in IC50. Conjugation of PE35 to a PSMA-binding urea improved 
Figure 4: PE35-MU2 is selectively toxic to PSMA producing cells. Viability 
of PIP-PC3 (A) or Flu-PC3 (B) cells  treated with naked PE35 (black) or PE35-
MU2 (red). Dose response curve LNCaP (top left), DU145 (top right), CWR22 
Rv1 (bottom left) or LAPC4 (bottom right) (C). Table depicting the IC50 values 
obtained on various cell lines with naked or conjugated PE35 (D). Pulse-soak 
experiment in which PIP-PC3, Flu-PC3, or CWR22 Rv1 were dosed with 250 
nM PE35-MU2 for 5 days (black bars) or pulsed for 24 hours (grey bars) (E). 
Light microscopy images of CWR22 Rv1 cells treated with 3 nM PE35-MU2 for  
5 days at 10x magnification  (F).  
115 
 
the potency on this drug on PIP-PC3 but not Flu-PC3, with the coupled-protein toxin 
having an IC50 of 0.9 nM against PIP cells (Figure 4A and 4B). We observed similar 
effects of the toxin on LNCaP, CWR22 Rv1, LAPC4, and DU145 cells in that both 
coupled and uncoupled material had a dose dependent cytotoxic effect on cell viability 
with IC50s consistent with the PIP and Flu cell data (Figure 4C). To assess the effect of 
urea conjugation on the ability of the toxin to kill cells we calculated the ratio of the IC50s 
of the naked and coupled protein with the higher ratios indicating that the conjugation 
improved the targeting of the toxin. We observe that all PSMA producing cell lines have 
a ratio above 1 and all PSMA negative lines have a ratio of approximately one (Figure 
4D). We also asked whether or not pulsing cells with the conjugate further enhanced 
Figure 5: PE35-MU2 is selectively internalized by PSMA expressing cells. 
Confocal microscopy images of PIP-PC3 or Flu-PC3 treated with Flor-PE35-
MU2 for one hour (A). PIP-PC3 cells treated with Flor-PE35-MU2 plus or 
minus 10 uM 2PMPA (B). Time course of Flor-PE35-MU2-treated PIP-PC3 
cells (C).  
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selectivity at high doses on PSMA producing cell lines. At a dose of 250 nM, the PSMA 
producing cell lines PIP and CWR22 Rv1 were killed regardless if they were exposed for 
24 hours or 5 days. Flu cells, however, were rescued from PE35-MU2 toxicity when 
pulsed with the drug for 24 hours (Figure 4E). Lastly, we visualized CWR22 Rv1 cells 
treated with the toxin at lethal doses at Day 5. While we clearly see a substantially 
decreased number of cells, we also see structural morphology consistent with apoptosis 
such as blebbing and shattering (Figure 4F).   
Like the GZMB, we assessed the uptake of Flor-PE35-MU2 using a confocal microscopy 
assay. Like the GZMB conjugate probe, we see vibrant labeling of the PIP-PC3 cells 
after a two hour treatment with 100 nM of the compound. We also observe some 
baseline uptake of the compound after exposure to Flu-PC3 cells for the same treatment 
conditions. Also like the GZMB-MU2 treatment, we observe a punctate staining pattern 
that appears to stain both the plasma membrane and the endosomal trafficking system. 
(Figure 5A). To ensure this effect was PSMA specific and not a result of a differential in 
uptake between PIP and Flu-PC3 cells, we treated PIP cells with either the PE35-MU2 
probe alone or the probe with 10 uM of the compound 2-PMPA, a potent competitive 
inhibitor of PSMA that has been shown to out compete the urea class of compounds for 
PSMA binding. When treated with this drug, we see ablation of fluorescein labeling on 
these cells (Figure 5B). Lastly, we aimed to observe if there was a change in signal over 
a time period of 24 hours. Compared to the 2 hour time point, we see no obvious 
differences in the intensity of the staining of the cells nor do we see a change in the 
pattern in terms of both dissemination and compartmentalization of the signal (Figure 
5C). 
Nude mice inoculated with PIP, Flu, and LNCaP xenografts were administered IV and IT 
injections of PE35-MU2 in order to assess the toxicity and efficacy of the construct. PIP  
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tumors injected IT with the protein-drug conjugate showed no change in tumor volume 
while control cells quadrupled in size. Flu xenografts, however, did not respond when 
injected with  the compound  and seemed to grow at a comparable rate to their control-
dosed counterparts (Figure 6A and 6B). To ensure that the toxin itself had little to no 
effect on these tumors, we injected LNCaP xenografts with 20 ug of both conjugated and 
unconjugated toxin. While the unconjugated grew roughly the same as the controls, we  
 
Figure 6: PE35-MU2 regresses PSMA expressing xenografts when 
injected intratumorly. Growth of PIP-PC3 (A) and Flu-PC3 (B) following two 
injections of vehicle (black) or 20 ug PE35-MU2 (red). LNCaP xenograft growth  
following two injections of either vehicle (black), 20 ug uncoupled PE35 (blue) 
or 20 ug PE35-MU2 (red) (C). PSA levels determined via ELISA of LNCaP-
bearing nude mice after 3 weeks of treatment (D). H & E staining of a PE35-




saw no change in tumor size of the conjugate-dosed xenografts after 2 weeks (Figure 
6D). Mice treated for an equal amount of time were measured for circulating PSA. We 
observed almost no detectable PSA in IT-injected PE35-MU2 mice compared to control 
animals (Figure 6D). To observe the tissue architecture of these tumors, we performed H 
& E staining on larger tumors dosed with the drug that responded via shrinkage. The 
remaining tissue  was mostly composed of dead, necrotic with viable cells visible at low 
abundance (Figure 6E). IV dosing of nude mice with two different doses of PE35-MU2 (2 
and 6 mpk) showed substantial body weight loss in the higher dose but less so in the 
lower dose with no animals perishing (data not shown). The 2 mpk dose was then 
selected for IV efficacy studies. We saw no major changes in tumor volume in either PIP 
or Flu mice injected with PE35-MU2 at this dose after 4 consecutive administrations of 
the drug (data not shown). Of the ten animals injected, two experienced lethal toxicity 
during this course of treatment suggesting that the 4 daily doses approached the 
maximum tolerated concentration of this drug in these animals.  
Discussion 
In this work, we have successfully shown that PSMA-binding ureas have the capacity to 
selectively, rapidly, and efficiently deliver cytotoxic protein payloads to cells producing 
the gene. These conjugates were synthesized fairly simply using cysteine-containing 
mutants of the protein toxins GZMB and PE35 and a maleimide-linked PSMA-binding 
urea. We chose these two agents due to their diverse mechanisms of action, need to be 
delivered into cells in order to be functional, and previous successes when fused to other 
targeting moieties such as antibodies. Using fluorescent and gel-based assays, we 
confirmed that coupling of our synthesized PSMA-binding urea compounds was simple, 
effective, and mostly quantitative. For the GZMB coupling, we observed complete 
ablation of disulfide dimer formation under non-reducing conditions using SDS PAGE 
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suggesting strongly that most of the cysteines on the protein were occupied by reacted 
ureas and unable to form these oligomers. The thiol selective fluorophore ABD-F 
showed a reduction of free thiols in solution once the MU2 molecule was coupled to 
PE35 under reducing conditions. We did observe some residual thiol present in the 
PE35-MU2 sample suggesting that some of this material had not fully coupled. At any 
rate, the ease of this chemistry suggests that the formation of similar conjugates is trivial 
and that other similar strategies can be employed for a diverse profile of therapeutic 
protein agents.  
Using an enzyme-coupled PSMA activity assay, we observed inhibition of PSMA by 
three different purified protein-urea conjugates. This assay traced the conversion of 
NAAG, a physiologically relevant and specific PSMA dipeptide substrate, to NAA and 
free glutamate and correlated PSMA inhibition with urea binding. None of the naked 
protein agents tested had any effect on this assay at any concentration tested. BSA-
MU2, GZMB-MU2, and PE35-MU2 all inhibited PSMA with IC50 values ranging from 
roughly 50 to 500 nM. We were somewhat surprised to see such a large range of 
potencies given that the linked urea did not change between the three. We interpret this 
result with two hypotheses. The first is that incomplete coupling (as what was possibly 
seen in the PE35-MU2 reaction) yielded naked protein in the sample threw off the 
calculation of the concentration of conjugated material present (A280 was used to 
determine protein-urea concentration). The other is that the urea molecule has different 
properties depending on what it’s linked to and that certain protein motifs can interact 
with the urea moiety and affect its ability to occupy the PSMA active site. We were 
encouraged, however, to see the PE35-MU2 construct internalize and kill cells very 
efficiently despite having the supposedly weakest binding to PSMA suggesting that this 
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assay alone cannot be used to predict the efficacy of a protein-urea conjugate with 
respect to cell internalization or function.  
We are disappointed to report that despite binding PSMA and being enzymatically 
active, GZMB-MU2 had no effect on cell viability at concentrations below 100 nM. As 
stated earlier, we did see toxicity on cells of GZMB-MU2 at concentrations higher than 
500 nM on DU145, CWR22 Rv1, and LNCaP. There did not seem to be a difference in 
this effect between conjugated and unconjugated protein suggesting that the mechanism 
was independent of PSMA uptake. It has been reported in the literature that GZMB can 
cleave and remodel members of the extracellular matrix and disrupt cell growth (22) 
which could explain why this effect is present in a system in which the protein does not 
seem to be entering the cells. Regardless, we were surprised to see rapid and specific 
uptake of the protein conjugate by PSMA-expressing PIP-PC3 cells despite no toxicity 
being observed. This and the punctate and non-diffuse staining pattern on the confocal 
images strongly suggests that GZMB-MU2 is being sequestered in the endosome of the 
cell and reaching its final destination in the perinuclear endosomal space. Localization of 
GZMB is crucial for its function and because the primary substrates of the protease are 
specific to the cell cytoplasm. It is likely then that this localization in the endosome is a 
limiting factor for this agent as a cytotoxic therapy. This result is consistent with GZMB’s 
function in the immune system, as its ability to induce cell death is dependent upon 
endosomal escape via perforin pores. This result, while not desired, elucidates the 
critical characteristics for a toxic payload must have when delivered by PSMA-urea 
molecules or other tumor-selective targeting molecules.  
Because the GZMB-MU2 molecule was unable to escape the endosomal 
compartmentalization following internalization via PSMA binding, we opted to utilize 
other means of targeting. We envision two solutions to overcome endosomal 
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entrapment. The first is to deliver a radio-isotope capable of inducing chromatin damage 
via proximity emission of radiation such as 177-Lu PSMA-617 (23) which does not need 
to exit the endosome. The other is to use a toxin that can efficiently exit this space once 
delivered. PE35 has been well characterized to access cytoplasmic its substrates 
following intracellular delivery despite the mechanism being somewhat unclear. We were 
pleased to see that where the GZMB compound failed, we observed success with the 
PE35-MU2. The conjugate selectively and potently targeted PSMA-expressing prostate 
cancer lines at concentrations up to two orders of magnitude lower than PSMA non-
expressing cells. We were also pleased to observe that naked PE35, while somewhat 
toxic to these cell lines, had IC50 values that were nearly identical to the urea conjugate 
on cells not expressing PSMA strongly suggesting that, again, this targeting is driven 
solely by PSMA expression. We also, using a fluorescent PE35-MU2 probe, observed 
specific uptake in PIP-PC3 cells but not in Flu PC3 cells whose only biological difference 
is production of the PSMA protein. To further confirm that this uptake was PSMA-driven 
and not an artifact of the cell lines, we showed disruption of PE35-MU2 internalization 
using a PSMA inhibitor, known as 2-PMPA, which binds to the active site of the enzyme 
and can out-compete the urea. Kinetic experiments showed that a majority of the net 
uptake of this drug occurs within the first two hours of exposure and is maintained for at 
least 24 hours, likely due to PSMA’s constant shuttling between the endosomal space 
and the plasma membrane. We rationalized that pulsing cells with this drug at high 
concentrations should minimize the non-specific toxicity of this protein on PSMA 
negative cells. When pulsed with PE-MU2, both PIP and CWR22 Rv1 cells were still 
killed rapidly but Flu-PC3 cells were not affected suggesting that non-specific toxicity of 
this protein is a slow, transient process that can be overcome by brief, high dose, pulses 
of the drug as opposed to constant exposure. Lastly, we were somewhat surprised to 
see no difference in staining pattern between the 2 and 24 hour time point, suggesting 
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that a majority of the PE35 cargo does not escape the endosome and that only a 
relatively small number of PE35 molecules are responsible for cell killing, as we begin to 
see cytotoxic effects of this drug on PSMA-producing cells at 24 hour time points. Based 
on the confocal time lapse experiment of PE35-MU2, it is possible that GZMB, at low 
levels is able to escape the endosome by itself at low levels but requires a much higher 
concentration of functional cytoplasmic enzyme to catalyze the activation of cell death 
pathways.  
We were encouraged to see that, when injected straight into the tumor, PE35-MU2 had 
an anti-tumor effect on PIP and LNCaP xenografts in nude mice but not Flu over the 
course of two to three weeks. These tumors did not change in volume compared to their 
size at the time of injection suggesting that the overall number of viable tumor tissue had 
decreased due to cell death matching our in vitro tissue culture experiments using this 
model. We were also pleased to see that the unconjugated protein had little to no effect 
on LNCaP xenografts. The lack of observable toxicity on Flu cells or with the uncouple 
protein suggests that a majority of the IT efficacy observed was PSMA specific and not 
due to non-specific uptake of the toxin or due to varied retention times of these 
constructs. PSA measurements in the LNCaP bearing mice also confirmed that the 
decrease in size observed was consistent with tumor burden. Histology of injected 
tumors also showed that a majority of the tissue had undergone cell death and that there 
was only a small portion of the remaining tumor that was viable. Unfortunately, despite 
having nice anti-tumor effects when injected IT and safe when administered IV at 
reasonable does, we did not observe any noticeable effect on PIP and Flu xenograft 
mice when injected with 2 MPK PE35-MU2 suggesting that the toxin does not have a 
preferable pharmacokinetic profile, consistent with some of the observed limitations of 
other anti-body drug conjugates containing PE-based payloads. Conjugation of this 
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construct to HSA, an Fc domain, or using more PEGylated linkers may improve the 
systemic availability of this targeted toxin thus making it a better pharmacophore (24).  
A vast majority of cytotoxic proteins and small molecules used for cancer chemotherapy 
have been targeted to tumors using protein-based Trojan horse strategies. Usually, 
these strategies employ the use of monoclonal antibodies, growth factors, or single 
chain variable fragments. In this work, we show the delivery of cytotoxic protein payloads 
to tumor cells using a small molecule inhibitor Trojan horse. This method has some 
advantages over protein targeted strategies, as these agents may have longer half-lives 
and are less susceptible to immunological responses that limit therapeutic application. 
This work introduces a novel PSMA-selective therapeutic agent containing a potent 
bacterial toxin. This agent was very impressive in in vitro and some in vivo models but 
was not particularly efficacious in IV dosing experiments. Other biochemical engineering 
approaches may be able to improve the half-life of these conjugates.  Because some 
toxicity was observed in vivo, reducing off-target toxicity via disruption of cell uptake 
mechanisms or using toxins with a larger therapeutic index could also improve the IV 
efficacy of these agents. Regardless, these results display a novel method to deliver 
cytotoxic proteins to cancer cells and may lay the groundwork for other ligand-targeted 
cytotoxic therapies to be developed. Another potential problem could be that the thiol-
ester linkage formed by the cysteine-maleimide linkage may be disrupted via a sulfhydryl 
replacement reaction with free albumin in vivo (25). Recently developed, more-stable 
linker technology may help to remedy this problem (26).  Ultimately, these PSMA-ureas 
offer an exciting new method to concentrate pharmaceutic agents into cells in a selective 
manner via trivial, gentle, and cheap chemical means and are an interesting addition to 





1. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary 
CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, 
Cronin KA (eds). SEER Cancer Statistics Review, 1975-2013, National Cancer 
Institute. Bethesda, MD. 
2. Chang SS. Overview of Prostate-Specific Membrane Antigen. Reviews in  
 
Urology. 2004;6 (Suppl 10):S13-S18. 
 
3. Carter RE, Feldman AR, Coyle JT. Prostate-specific membrane antigen is a 
hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. 
Proc Natl Acad Sci USA. 1996;93(2):749-53. 
4. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane 
antigen expression is greatest in prostate adenocarcinoma and lymph node 
metastases. Urology. 1998;52(4):637-40. 
5. Lapidus RG, Tiffany CW, Isaacs JT, Slusher BS. Prostate-specific membrane 
antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate. 
2000;45(4):350-4. 
6. Haffner MC, Kronberger IE, Ross JS, et al. Prostate-specific membrane antigen 
expression in the neovasculature of gastric and colorectal cancers. Hum Pathol. 
2009;40(12):1754-61. 
7. Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V, Rahmati R, Bander 
NH. 1998. Constitutive and antibody-induced internalization of prostate-specific 




8. Naveed H. Akhtar, Orrin Pail, Ankeeta Saran, Lauren Tyrell, and Scott T. 
Tagawa, “Prostate-Specific Membrane Antigen-Based Therapeutics,” Advances 
in Urology, vol. 2012, Article ID 973820, 9 pages, 2012.  
9. Will L, Sonni I, Kopka K, Kratochwil C, Giesel FL, Haberkorn U. Radiolabelled 
PSMA small molecule inhibitors. Q J Nucl Med Mol Imaging. 
2017;48(supplement 2):25P. 
10. Chen Y, Dhara S, Banerjee SR, et al. A Low Molecular Weight PSMA-Based 
Fluorescent Imaging Agent for Cancer. Biochemical and biophysical research 
communications. 2009;390(3):624-629.  
11. Greish K. Enhanced permeability and retention (EPR) effect for anticancer 
nanomedicine drug targeting. Methods Mol Biol. 2010;624:25-37. 
12. Hoves S, Trapani JA, Voskoboinik I. The battlefield of perforin/granzyme cell 
death pathways. J Leukoc Biol. 2010;87(2):237-43. 
13. Cullen SP, Adrain C, Lüthi AU, Duriez PJ, Martin SJ. Human and murine 
granzyme B exhibit divergent substrate preferences. The Journal of Cell Biology. 
2007;176(4):435-444.  
14. Keefe D, Shi L, Feske S, et al. Perforin triggers a plasma membrane-repair 
response that facilitates CTL induction of apoptosis. Immunity. 2005;23(3):249-
62. 
15. Thiery J, Keefe D, Boulant S, et al. Perforin pores in the endosomal membrane 
trigger release of endocytosed granzyme B to the cytosol of target cells. Nature 
immunology. 2011;12(8):770-777.  
16. Wolf P, Elsässer-beile U. Pseudomonas exotoxin A: from virulence factor to anti-
cancer agent. Int J Med Microbiol. 2009;299(3):161-76. 
126 
 
17. Chaudhary VK, FitzGerald DJ, Adhya S, Pastan I. Activity of a recombinant 
fusion protein between transforming growth factor type alpha 
and Pseudomonas toxin. Proc Natl Acad Sci USA. 1987;84:4538–4542.  
18. Wolf P, Elsässer-beile U. Pseudomonas exotoxin A: from virulence factor to anti-
cancer agent. Int J Med Microbiol. 2009;299(3):161-76. 
19. Kreitman RJ, Tallman MS, Robak T, et al. Phase I Trial of Anti-CD22 
Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in 
Patients With Hairy Cell Leukemia. Journal of Clinical Oncology. 
2012;30(15):1822-1828.  
20. Marasca KP, Hillier SM, Femia FJ. Barone D, Joyal JL, Zimmerman CN, 
Kozikowski AP, Barrett JA, Eckelman WC, Babich JW. A series of halogenated 
heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as 
radiolabeled probes for targeting prostate cancer. J. Med. Chem. 52: 347-357 
(2009). 
21. Gehrmann M, Doss BT, Wagner M, et al. A novel expression and purification 
system for the production of enzymatic and biologically active human granzyme 
B. J Immunol Methods. 2011;371(1-2):8-17. 
22. Buzza MS, Zamurs L, Sun J, et al. Extracellular matrix remodeling by human 
granzyme B via cleavage of vitronectin, fibronectin, and laminin. J Biol Chem. 
2005;280(25):23549-58. 
23. Kratochwil C, Giesel FL, Stefanova M, et al. PSMA-Targeted Radionuclide 
Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled 
PSMA-617. J Nucl Med. 2016;57(8):1170-6. 
24. Strohl WR. Fusion Proteins for Half-Life Extension of Biologics as a Strategy to 
Make Biobetters. Biodrugs. 2015;29(4):215-239.  
127 
 
25. Shen BQ, Xu K, Liu L, et al. Conjugation site modulates the in vivo stability and 
therapeutic activity of antibody-drug conjugates. Nat Biotechnol. 2012;30(2):184-
9. 
26. Lyon RP, Setter JR, Bovee TD, et al. Self-hydrolyzing maleimides improve the 






Oliver C Rogers, BS 
PhD Candidate- Johns Hopkins University 
E-mail: orogers18@gmail.com 
Born 
September 26, 1989 
Columbus, Ohio 
Education 
August 2012- March 2017: PhD, Pharmacology & Molecular Sciences  
                                    Johns Hopkins Medical Institutions, Baltimore MD, 21287 
                                    Thesis Advisor: Dr. Samuel R. Denmeade, M.D. 
                                    Thesis: “Novel Methods of Targeting Protein Cytotoxins to   
                                    Metastatic Prostate Tumors”                       
Sept 2008- June 2012: Bachelor of Science, Biology  
                                     Minor, Chemistry 
                                     University of Cincinnati, Cincinnati, OH 45219 
                                     GPA: 3.515 
 
Research Interests 
 Protein Engineering 
 Pharmacology 
 Cancer Biology & Oncology 
 Enzymology                                 
129 
 
Research Positions Held 
 
Academic and Professional Honors 
Scheinberg Travel Award- Johns Hopkins Medical Institutions- Fall 2015 
Voted “Best Scientific Contribution” Univ. of Cincinnati SURF Research 
Presentations- Summer 2011 
ASPET Summer Undergraduate Research Fellowship (SURF) (Univ. of 
Cincinnati)- Summer 2011 
University of Cincinnati Dean’s List: Fall 2008, Winter 2009, Spring 2009, Fall 
2010, Spring 2011, Fall 2011, Winter 2012 
Named University of Cincinnati FYE Peer Mentor-Fall 2009  
University of Cincinnati Cincinnatus Century Scholarship- Fall 2008 
Memberships in Professional Societies 
American Association for the Advancement of Science (Graduate) 
American Society for Pharmacology and Experimental Therapeutics 
(Undergraduate)  
Position Start  End  Institution Supervisor 
Staff Scientist Apr-17 Present Revolve Biotech  Elad Firnberg, PhD 
Graduate 
Student Aug-12 Mar-17 Johns Hopkins University Sam Denmeade, MD 
Research 
Assistant Aug-11 Jun-12 University of Cincinnati Terence Kirley, PhD 
Undergraduate 
Fellow Jun-11 Aug-11 University of Cincinnati Terence Kirley, PhD 
Student 






Rogers OC, Anthony L, Rosen DM,  Therres JA, Das D, Yang X, Minn I, Mease 
R, Pomper M, Denmeade SR2Targeted Delivery of Cytotoxic Proteins via Small 
Molecule Peptidase Inhibitors. 2017. In preparation.  
Rogers OC, Antony L, Brennen WN, Denmeade SR, PSA-Activated Serine 
Proteases as a Novel Therapeutic Strategy to Target Prostate Cancer. 2017. In 
Preparation. 
Rogers OC, Pruitt F, Antony L, Kizewski A, Kisteman LN, Karp JM, Howard P, 
Denmeade SR, Isaacs, JI, Brennen WN. PLGA Microparticle Encapsulation of a 
Novel Prostate-Targeted Biologic For Tumor Delivery: Characterization of 
Release and Functionality. 2017 In preparation. 
Rogers OC, Yen HR,  Solomon A, Abi-Habib R, Buckley JT, Drake CG, 
Denmeade SR. A Potent IL-2R Targeting Pro-drug as a Novel Anti-tumor 




Engineering Human Granzyme B to Target Prostate Cancer Cells. 3rd Annual 






Rogers O, Antony L, Brennen W, Denmeade SR: Engineered Serine Proteases 
as Novel Prostate Cancer Therapeutics. Multi-Institutional Prostate Cancer 
Program Retreat. March 2016. Ft. Lauderdale, FL. 
Rogers O, Antony L, Brennen W, Denmeade SR, Engineering Human 
Granzyme B to Target Prostate Cancer Cells. 3rd Annual Proteins and 
Antibodies Therapeutics, October 2015, Boston, MA.  
 
Rogers O, Antony L, Brennen W, Denmeade S, Proaerolysin Based Chimeric 
Protoxins: A Novel Therapy for Metastatic Prostate Cancer. Multi-Institutional 
Prostate Cancer Program Retreat. March 2014. Ft. Lauderdale, FL. 
 
Teaching/Mentoring 
Johns Hopkins Medical Institutions- MERIT/SHARP- Student Mentor- July 2015-
July 2016 
University of Cincinnati Center For First Year Education- Peer Leader and 
Mentor- September 2009- June 2011 
